Marex Group plc (NASDAQ: MRX) outlines extensive risk factors in annual 20-F
Marex Group plc, a U.K.-based financial services firm, has filed its annual Form 20‑F, reporting under IFRS Accounting Standards and listing 72,937,470 ordinary shares outstanding as of year end. The company’s ordinary shares, par value $0.001551, trade on the NASDAQ Global Select Market under the symbol MRX.
The report emphasizes extensive risk factors tied to commodity market volatility, geopolitical events, interest and foreign exchange rates, client and counterparty defaults, and global regulatory complexity. Marex highlights operational and cybersecurity risks, including past cyber incidents at key vendors, growing use of artificial intelligence tools, and exposure to cryptocurrencies through derivatives and structured products.
Additional risks include climate‑change impacts on commodity markets, intense competition, challenges in recruiting and retaining key brokers, litigation and arbitration exposure, dependence on exchange memberships and clearing infrastructure, and integration and due‑diligence risks from an acquisitive growth strategy. As a foreign private issuer, Marex follows less frequent U.S. reporting requirements and warns that identified material weaknesses in internal control over financial reporting could affect the reliability and timing of future financial statements.
Positive
- None.
Negative
- None.
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 | |
OR | |
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |
For the fiscal year ended | |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |
OR | |
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
☒ | Non-accelerated filer | ☐ | ||
Accelerated filer | ☐ | Emerging growth company |
U.S. GAAP | ☐ | Accounting Standards Board | ☒ | Other | ☐ |
Item 1.Identity of Directors, Senior Management and Advisers | 6 |
Item 2.Offer Statistics and Expected Timetable | 6 |
Item 3.Key Information | 6 |
A.[Reserved] | 6 |
B.Capitalization and Indebtedness | 6 |
C.Reasons for the Offer and Use of Proceeds | 6 |
D.Risk Factors | 6 |
Item 4. Information on the Company. | 51 |
A.History and Development of the Company | 51 |
B.Business Overview | 52 |
C.Organizational Structure | 76 |
D.Property, Plant and Equipment | 76 |
Item 4A.Unresolved Staff Comments | 77 |
Item 5.Operating and Financial Review and Prospects | 78 |
A.Operating Results | 86 |
B.Liquidity and Capital Resources | 97 |
C.Research and Development, Patents and Licenses, etc. | 102 |
D.Trend Information | 102 |
E.Critical Accounting Estimates | 102 |
Item 6.Directors, Senior Management And Employees | 103 |
A.Directors and Senior Management | 103 |
B.Compensation | 105 |
C.Board Practices | 154 |
D.Employees | 156 |
E.Share Ownership | 157 |
F.Disclosure of a Registrant’s Action to Recover Erroneously Awarded Compensation | 157 |
Item 7.Major Shareholders and Related Party Transactions | 157 |
A.Major Shareholders | 157 |
B.Related Party Transactions | 159 |
C.Interests of Experts and Counsel | 160 |
Item 8.Financial Information | 161 |
A.Consolidated Statements and Other Financial Information | 161 |
B.Significant Changes | 162 |
Item 9.The Offer and Listing | 162 |
A.Offer and Listing Details | 162 |
B.Plan of Distribution | 162 |
C.Markets | 162 |
D.Selling Shareholders | 162 |
E.Dilution | 162 |
F.Expenses of the Issue | 162 |
Item 10.Additional Information | 162 |
A.Share Capital | 162 |
B.Memorandum and Articles of Association | 162 |
C.Material Contracts | 163 |
D.Exchange Controls | 163 |
E.Taxation | 163 |
F.Dividends and Paying Agents | 170 |
G.Statement by Experts | 170 |
H.Documents on Display | 170 |
I.Subsidiary Information | 171 |
J.Annual Report to Security Holders | 171 |
Item 11.Quantitative and Qualitative Disclosures About Market Risk | 171 |
Item 12.Description of Securities Other Than Equity Securities | 178 |
Item 13.Defaults, Dividend Arrearages and Delinquencies | 178 |
Item 14.Material Modifications to the Rights of Security Holders and Use of Proceeds | 178 |
Item 15.Controls and Procedures | 179 |
A.Disclosure Controls and Procedures | 179 |
B.Management’s Annual Report on Internal Control Over Financial Reporting | 179 |
C.Attestation Report of the Registered Public Accounting Firm | 181 |
D.Changes in Internal Control Over Financial Reporting | 183 |
Item 16.[Reserved] | 183 |
Item 16A.Audit Committee Financial Expert | 183 |
Item 16B.Code of Ethics | 183 |
Item 16C.Principal Accountant Fees and Services | 183 |
Item 16D.Exemptions from the Listing Standards for Audit Committees | 184 |
Item 16E.Purchases of Equity Securities by the Issuer and Affiliated Purchasers | 184 |
Item 16F.Change in Registrant’s Certifying Accountant | 184 |
Item 16G.Corporate Governance | 184 |
Item 16H.Mine Safety Disclosure | 185 |
Item 16I.Disclosure Regarding Foreign Jurisdictions That Prevent Inspections | 185 |
Item 16J.Insider Trading Policies | 185 |
Item 16K.Cybersecurity | 185 |
Item 17.Financial Statements | 187 |
Item 18.Financial Statements | 187 |
Item 19.Exhibits | 188 |
Property Name | Sq Ft | City | Occupancy Type | Lease end Date |
155 Bishopsgate, London EC2M 3TQ, level 2 | 15,188 | London | Leased | August 11, 2028 |
155 Bishopsgate, London EC2M 3TQ, level 3 | 20,857 | London | Leased | October 30, 2035 |
155 Bishopsgate, London EC2M 3TQ, level 4 | 16,813 | London | Leased | October 30, 2035 |
155 Bishopsgate, London EC2M 3TQ, level 5 | 37,355 | London | Leased | October 30, 2035 |
Riverbank House, 2 Swan Lane, London, EC4R 3AD | 34,521 | London | Leased | November 15, 2035 |
42 Rue Washington and 29 Rue de Berri, Floors 1 & 5, 1st & 4th Basement | 21,701 | Paris | Leased | January 10, 2033 |
222 W. Adams St, Suite 450, Chicago, Illinois 60606 | 21,580 | Chicago | Leased | December 31, 2029 |
140 E 45th St 10th & 11th Floor, 2 Grand Central Tower, New York 10017 | 25,058 | New York | Leased | July 31, 2030 |
Year Ended December 31, | ||
2025 | 2024 | |
(m) | ||
$ | $ | |
Consolidated income statement | ||
Commission and fee income ............................................................................................... | 1,823.0 | 1,618.1 |
Commission and fee expense ............................................................................................. | (845.5) | (762.0) |
Net commission income ................................................................................................... | 977.5 | 856.1 |
Net trading income ............................................................................................................. | 851.9 | 492.4 |
Interest income ...................................................................................................................... | 912.8 | 765.2 |
Interest expense .................................................................................................................... | (760.2) | (538.1) |
Net interest income ............................................................................................................ | 152.6 | 227.1 |
Net physical commodities income ................................................................................. | 42.1 | 19.1 |
Revenue ............................................................................................................................ | 2,024.1 | 1,594.7 |
Expenses | ||
Compensation and benefits ............................................................................................ | (1,234.2) | (971.1) |
Depreciation and amortisation ....................................................................................... | (36.1) | (29.5) |
Other expenses ................................................................................................................ | (353.9) | (306.3) |
Net recovery of credit losses .......................................................................................... | 0.7 | 1.7 |
Bargain purchase gain on acquisitions .............................................................................. | 3.6 | — |
Other income ......................................................................................................................... | 7.4 | 6.3 |
Profit before tax from continuing operations .............................................................. | 411.6 | 295.8 |
Tax ...................................................................................................................................... | (103.7) | (77.8) |
Profit after tax from continuing operations ................................................................. | 307.9 | 218.0 |
Loss after tax from discontinued operations .............................................................. | (0.2) | — |
Profit after tax ...................................................................................................................... | 307.7 | 218.0 |
Years Ended December 31, | ||
2025 | 2024 | |
(m) | ||
Revenue | $ | $ |
Clearing ........................................................................................................................... | 528.2 | 466.3 |
Agency and Execution .................................................................................................. | 1,049.2 | 695.2 |
Market Making ................................................................................................................ | 235.5 | 207.8 |
Hedging and Investment Solutions ............................................................................. | 196.8 | 161.5 |
Corporate ........................................................................................................................ | 14.4 | 63.9 |
Total Revenue ...................................................................................................................... | 2,024.1 | 1,594.7 |
Adjusted Profit Before Tax¹ .............................................................................................. | ||
Clearing ........................................................................................................................... | 261.5 | 247.3 |
Agency and Execution .................................................................................................. | 280.9 | 107.9 |
Market Making ................................................................................................................ | 68.9 | 65.6 |
Hedging and Investment Solutions ............................................................................. | 43.5 | 42.0 |
Corporate ........................................................................................................................ | (236.7) | (141.7) |
Total Adjusted Profit Before Tax¹ ................................................................................... | 418.1 | 321.1 |
Year Ended December 31, | |||
2025 | 2024 | 2023 | |
($m, except percentage, earnings per share and ratio) | |||
Non-IFRS Measures | |||
Adjusted Profit Before Tax .............................................................. | 418.1 | 321.1 | 230.0 |
Adjusted Profit Before Tax Margin ................................................ | 20.7% | 20.1% | 18.5% |
Adjusted Profit After Tax Attributable to Common Equity .......... | 303.9 | 231.0 | 162.6 |
Adjusted Return on Equity ............................................................. | 29.9% | 29.8% | 26.0% |
Adjusted Basic Earnings per Share ($)1 ...................................... | $4.26 | $3.34 | $2.46 |
Adjusted Diluted Earnings per Share ($)2 .................................... | $3.99 | $3.07 | $2.31 |
Adjusted Sharpe ratio ..................................................................... | 6.3 | 5.2 | 4.3 |
Years Ended December 31, | |||
2025 | 2024 | 2023 | |
($ millions, except percentage and per share data) | |||
Profit After Tax | 307.7 | 218.0 | 141.3 |
Loss After Tax from Discontinued Operations | 0.2 | — | — |
Profit After Tax from Continuing Operations | 307.9 | 218.0 | 141.3 |
Tax | 103.7 | 77.8 | 55.2 |
Goodwill impairment charge¹ | — | — | 10.7 |
Bargain purchase gains2 | (3.6) | — | (0.3) |
Amortisation of acquired brands and customer lists3 | 6.9 | 5.5 | 2.1 |
Activities relating to shareholders4 | — | 2.4 | 3.1 |
Employer tax on vesting of the growth shares5 | — | 2.2 | — |
Owner fees6 | 0.4 | 2.4 | 6.0 |
IPO preparation costs7 | — | 8.6 | 10.1 |
Fair value of the cash settlement option on the growth shares8 | — | 2.3 | — |
Public offering of ordinary shares9 | 1.3 | 1.9 | — |
Acquisition costs10 | 1.5 | — | 1.8 |
Adjusted Profit Before Tax | 418.1 | 321.1 | 230.0 |
Tax and the tax effect on the Adjusting Items11 | (100.4) | (76.8) | (54.1) |
Profit attributable to AT1 note holders12 | (13.3) | (13.3) | (13.3) |
Profit attributable to non-controlling interest13 | (0.5) | — | — |
Adjusted Profit after Tax Attributable to Common Equity | 303.9 | 231.0 | 162.6 |
Profit after Tax Margin from Continuing Operations (%) | 15.2% | 13.7% | 11% |
Adjusted Profit Before Tax Margin14 | 20.7% | 20.1% | 18% |
Basic Earnings per Share15 | $4.12 | $2.96 | $1.94 |
Diluted Earnings per Share16 | $3.86 | $2.72 | $1.82 |
Adjusted Basic Earnings per Share15 | $4.26 | $3.34 | $2.46 |
Adjusted Diluted Earnings per Share16 | $3.99 | $3.07 | $2.31 |
Common Equity17 | 1,017.9 | 775.6 | 629.2 |
Adjusted Return on Equity (%) | 29.9% | 29.8% | 26% |
Year Ended December 31, | |||
2025 | 2024 | 2023 | |
(millions, except ratios) | |||
Average monthly Profit After Tax ................................................... | $25.6 | $18.2 | $11.8 |
Standard deviation on monthly profit after tax(a) ......................... | $3.9 | $3.9 | $5.9 |
Sharpe ratio .................................................................................... | 6.5 | 4.7 | 2.0 |
Average monthly Adjusted Profit Before Tax ............................... | $34.9 | $26.8 | $19.2 |
Standard deviation on monthly Adjusted Profit Before Tax(a) .... | $5.5 | $5.2 | $4.5 |
Adjusted Sharpe ratio .................................................................. | 6.3 | 5.2 | 4.3 |
Year Ended December 31, | |||
2025 | 2024 | 2023 | |
FTE .................................................................................................... | 3,282 | 2,425 | 2,167 |
Average FTE .................................................................................... | 2,786 | 2,334 | 1,914 |
Average front-office FTE ................................................................ | 1,405 | 1,250 | 1,028 |
Revenue per front-office FTE ($m) .............................................. | 1.4 | 1.3 | 1.2 |
Adjusted Profit After Tax Attributable to Common Equity per FTE ($’000) ...................................................................................... | 109 | 99 | 84 |
Active clients1 .................................................................................. | 3,465 | 2,910 | 2,605 |
Average balances ($bn) ................................................................. | 18.3 | 13.5 | 12.9 |
Contracts cleared (m) ..................................................................... | 1,280 | 1,116 | 856 |
Total Capital Ratio (%) .................................................................. | 230 | 234 | 229 |

Years Ended December 31, | ||
2025 | 2024 | |
(m) | ||
$ | $ | |
Net cash from operating activities ........................................................................... | 667.5 | 1,163.5 |
Net cash used in investing activities ....................................................................... | (264.3) | (35.3) |
Net cash used in financing activities ....................................................................... | (123.9) | (37.2) |
Contractual Obligations | Total | On demand | Less than 3 months | 3 to 12 months | 1 to 5 years | More than 5 years |
(m) | ||||||
Repurchase agreements ............................. | 4,148.9 | — | 4,148.9 | — | — | — |
Short securities ............................................. | 2,215.7 | — | 2,215.7 | — | — | — |
Amounts due to exchanges, clearing houses and other counterparties ................ | 378.3 | 378.3 | — | — | — | — |
Amounts due to Prime Brokers .................. | 733.6 | 733.6 | — | — | — | — |
Amounts payable to clients ......................... | 8,951.7 | 8,951.7 | — | — | — | — |
Other creditors .............................................. | 129.9 | 6.6 | 113.2 | 10.1 | — | — |
Stock lending ................................................. | 5,496.7 | 5,496.7 | — | — | — | — |
Settlement balances ..................................... | 2,096.4 | — | 2,096.4 | — | — | — |
Short-term borrowings ................................. | 200.0 | 200.0 | — | — | — | — |
Debt securities .............................................. | 5,721.6 | — | 2,148.2 | 1,246.1 | 2,256.8 | 70.5 |
Lease liabilities .............................................. | 127.6 | — | 3.1 | 10.0 | 75.0 | 39.5 |
Bank overdrafts ............................................. | 67.2 | 67.2 | — | — | — | — |
Total non-derivative financial liabilities as of December 31, 2025 ........ | 30,267.6 | 15,834.1 | 10,725.5 | 1,266.2 | 2,331.8 | 110.0 |
Total | On demand | Less than 3 months | 3 to 12 months | 1 to 5 years | More than 5 years | |
(m) | ||||||
Repurchase agreements ............................. | 2,305.8 | — | 2,305.8 | — | — | — |
Short securities ............................................. | 1,704.6 | — | 1,704.6 | — | — | — |
Amounts due to exchanges, clearing houses and other counterparties ................ | 1,407.5 | 1,218.8 | 188.0 | 0.7 | — | — |
Amounts due to Prime Brokers .................. | 1,017.1 | 1,017.1 | — | — | — | — |
Amounts payable to clients ......................... | 6,236.9 | 6,236.9 | — | — | — | — |
Other creditors .............................................. | 116.0 | 9.6 | 96.8 | 7.3 | 2.3 | — |
Stock lending ................................................. | 4,952.1 | 4,804.5 | 147.6 | — | — | — |
Settlement balances ..................................... | 482.3 | — | 482.3 | — | — | — |
Short-term borrowings ................................. | 152.0 | — | 152.0 | — | — | — |
Debt securities .............................................. | 3,604.5 | — | 1,235.8 | 883.8 | 1,434.9 | 50.0 |
Lease liabilities .............................................. | 104.3 | — | 3.7 | 10.3 | 52.9 | 37.4 |
Total non-derivative financial liabilities as of December 31, 2024 ........ | 22,083.1 | 13,286.9 | 6,316.6 | 902.1 | 1,490.1 | 87.4 |
Name | Age | Position |
Executive Officers | ||
Ian Lowitt ....................................................... | 62 | Chief Executive Officer and Director |
Rob Irvin ........................................................ | 48 | Chief Financial Officer and Director |
Paolo Tonucci ............................................... | 57 | Chief Strategist and CEO of Capital Markets |
Simon van den Born .................................... | 58 | President |
Thomas Texier .............................................. | 52 | Group Head of Clearing |
Nilesh Jethwa ............................................... | 47 | Chief Executive Officer of Marex Solutions |
Board of Directors | ||
Robert Pickering ........................................... | 66 | Chair |
Konstantin Graf von Schweinitz ................. | 64 | Director |
Sarah Ing ....................................................... | 59 | Director |
Linda Myers .................................................. | 61 | Director |
John W. Pietrowicz ...................................... | 61 | Director |
Element, purpose and link to strategy | Operation | Maximum opportunity | Performance measures |
Base salary Element of fixed pay that reflects the individual’s role, position, experience and contribution to the Group | Base salaries are paid in cash and typically reviewed annually, with any changes normally taking effect from January 1. Out-of-cycle reviews may be conducted if considered appropriate by the Committee. Base salaries are typically set with reference to comparator groups consisting of peers in the global financial services sector and wider industry. The Committee has the flexibility to set the salary of a new hire at a discount to the market and to realign it in subsequent years as the individual gains experience in the role. In exceptional circumstances, the Committee may agree to pay above market levels to secure or retain an individual who is considered by the Committee to possess significant and relevant experience that is critical to the delivery of the business strategy. | There is no prescribed maximum, annual increases will normally be made with reference to wider business performance, economic indicators, and increases made to the wider workforce. Higher increases may be made, for example, where there have been significant changes in the responsibility in a role, to recognise experience, where there are large variances to the market, in the case of a new Executive Director appointed on a salary below the market rate, or where there is a significant change in the relationship of the Company relative to a peer group. | Not applicable. |
Pension To provide a market competitive level of retirement provision | Mandatory retirement provision required by law (or similar) in the jurisdiction in which the Executive Director is resident will be provided. Pension provision is provided in the form of a defined contribution (DC) pension. | Any mandatory retirement provision required by law (or similar) in the jurisdiction in which the Executive Director is resident will be provided. Currently Executive Directors are entitled to an employer pension contribution of 6% of base salary up to a base of £123,600. Any changes to pension provision or opportunity to elect for a cash allowance instead of a pension contribution will be aligned to the pension provision available to all other qualifying employees. | Not applicable. |
Element, purpose and link to strategy | Operation | Maximum opportunity | Performance measures |
Benefits To provide a market competitive level of benefits | Benefits that are currently provided include private medical, life insurance and income protection. The Committee can provide additional benefits it deems reasonable. | There is no defined maximum. Benefits are set at what are in the Committee’s opinion reasonable taking into account wider Company policy, market practice and individual circumstances. The Committee regularly reviews benefit costs to ensure they are appropriate and affordable. | Not applicable. |
Element, purpose and link to strategy | Operation | Maximum opportunity | Performance measures |
Annual bonus To motivate employees and incentivize delivery of annual performance targets | Annual bonuses may be paid partly in cash and partly in deferred equity pursuant to the Company's Deferred Bonus Programme (DBP) under the Global Omnibus Plan. The Committee will have regard to relevant regulatory requirements when determining the form and length of any deferral arrangements. Performance targets are normally set at the beginning of the performance period and are assessed at the end of the financial period. The Committee has discretion to adjust the formulaic outcome upwards or downwards to ensure outcomes reflect overarching Company performance and/or management contribution. Any adjustment made using this discretion will be explained. Malus and clawback apply. Refer to the notes to the policy table. Awards are still outstanding under legacy deferred bonus plans. Refer to the notes to the policy table. | The maximum annual bonus that may be awarded will be 600% of salary. The maximum opportunity for each year will be advised to the CEO and CFO at the beginning of the performance year. | Performance measures may include both business and individual performance and may include a combination of financial and non-financial measures. The majority of the bonus will be linked to financial performance. Detail on performance measures and the associated rationale for their selection will be disclosed in the relevant annual report. The Committee has discretion to amend performance measures and targets after they have been set if events occur that the Committee considers mean that the original performance measures and/or targets are no longer a fair test of performance |
Equity incentives to motivate and incentivize delivery of sustained, long-term performance and to align participants’ interests to that of shareholders | Allows for grants of equity incentive awards under the Global Omnibus Plan. Executive Directors are eligible to participate in equity incentive programmes that are implemented under the Global Omnibus Plan from time to time Equity awards are typically made in the form of performance shares under the Long-term Incentive Plan (LTIP) linked to Group performance over a three-year performance period. Both the Executive Directors participate in an annual LTIP and the CFO has been awarded a one-off retention long term incentive plan award (RLTIP) granted in connection with the IPO. The Committee may deem it appropriate to deliver LTIP awards in other forms or using alternative vehicles under the Global Omnibus Plan. These vehicles may include, but are not limited to, share options, restricted shares, restricted stock units, performance shares, performance share units, phantom stock, and/or any other equity-based or cash-based LTI instruments as may be considered appropriate from time to time. When determining award values and the form of vehicle used, the Committee will consider the certainty of value associated with the relevant delivery vehicle and have due regard for the overall limits in the policy Under the LTIP and RLTIP, the Committee has discretion to allow participants to receive dividend equivalents in relation to the period between grant and vesting in respect of awards that vest. The Committee has discretion to adjust the formulaic outcome upwards or downwards to ensure outcomes reflect overarching Company performance and/or management contribution. Any adjustment made using this discretion will be explained. Malus and clawback apply. Refer to the notes to the policy table. The CEO has an outstanding award under a legacy annual long term incentive. Refer to the notes to the policy table. | The maximum annual long- term incentive award that may be awarded for each year is up to 200% of Base Salary with the actual level of awarded determined each year. Typically, under the LTIP, 50% of the maximum award typically vests for achieving threshold performance, increasing on a graduated scale to 100% of the maximum opportunity vesting for achieving maximum performance. For exceptional performance, the number of shares receivable will increase by 15% (i.e. up to 230% of salary if a 200% of base salary grant is made and if the pre-set exceptional performance target for the three year performance period has been met. | The Committee selects performance measures that support the Company’s long- term strategic priorities, provide a direct link with shareholder value and ensure a clear line of sight for participants between performance and reward. Detail on performance measures and the associated rationale for their selection will be disclosed in the relevant annual report. The Committee has discretion to amend performance measures and targets after they have been set if events occur that the Committee considers mean that the original performance measures and/or targets are no longer a fair test of performance. |
Notice period | The notice period would be 12 months in the case of notice being given by both the Company and the Executive Director. An Executive Director may be placed on garden leave during the notice period. |
Payment in lieu of notice ("PILON") | The contract may include provision for the contract to be terminated summarily by paying a PILON comprising basic salary and pension for the remainder of the notice period. PILON will not apply on termination for misconduct. The Company will have discretion to pay on a phased basis, subject to mitigation. |
Retirement benefits | The service contract may include entitlement to retirements benefits, subject to the provisions and limits set out in this Remuneration Policy. The entitlement to retirement benefits may continue during any notice period. |
Benefits | The service contract may include entitlement to other benefits, subject to the provisions and limits set out in this Remuneration Policy. The entitlement to other benefits may continue during any notice period. |
Cash and Equity incentive plans | The Executive Director will be eligible to be considered (at the Committee's discretion) to participate in the Company's annual bonus arrangements and long term incentive arrangements (whether cash or equity based). Participation in such arrangements will be subject to the provisions and limits set out in this Remuneration Policy. |
Element | Operation | Maximum Opportunity | Performanc e Measures |
Fees To attract and retain high-calibre Non- Executive Directors | Fees will typically consist of a basic fee for Non-Executive Director responsibilities plus incremental fees for additional roles/responsibilities such as membership and chairmanship of Board committees and the Senior Independent Non-Executive Director role. The Non-Executive Directors receive a portion of their fees in cash and a portion in the form of an award of additional shares (see Equity Awards section). The Non-Executive Directors do not receive any pension from the Company, nor do they participate in any performance-related incentive plans. | There is no prescribed maximum. The fee levels are reviewed on an annual basis and may be increased by the Group taking into account factors such as wider economic conditions, the time commitment of the role, and market levels in comparable companies. | Not applicable. |
Benefits To reimburse Directors for reasonable expenses incurred | Non-Executive Directors may receive travel, accommodation and other business-related expenses incurred in carrying out their duties. Non-Executive Directors are entitled to receive officers' liability insurance. Other reasonable benefits may be provided to Non-Executive Directors at the discretion of the Committee. | No formal maximum | Not applicable |
Equity Awards To attract and retain high-calibre Non- Executive Directors. For public companies listed in the United States, equity-based remuneration is a standard component of Non-Executive Director remuneration | As part of their fees, Non-Executive Directors are eligible to receive an annual fixed award over ordinary shares in the Company pursuant to the Non-employee Sub-Plan of the Global Omnibus Plan. Any shares awarded will not be subject to performance conditions. Awards vest on a daily basis over a 12 month period and are not subject to any post vesting sale restrictions. | No formal maximum | Not applicable |
Date of letter of appointment | Unexpired term at AGM | |
Robert Pickering | 6/5/2024 | 2 years |
Linda Myers | 6/5/2024 | 2 years |
Sarah Ing | 6/5/2024 | 2 years |
Konstantin Graf von Schweinitz | 6/5/2024 | 2 years |
John Pietrowicz | 6/5/2024 | 2 years |
g Fixed Remuneration | ||
g Annual Bonus | ||
g LTIP | ||

g Fixed Remuneration | ||
g Annual Bonus | ||
g LTIP | ||

Ian Lowitt | Rob Irvin | |||||
20251 | 20242 | 20251 | 20242 | |||
$'000 | $'000 | $'000 | $'000 | |||
Fixed Pay | Salary | 1,317 | 1,280 | 658 | 608 | |
Benefits | 25 | 19 | 2 | 2 | ||
Pension | - | - | 10 | 9 | ||
Total fixed remuneration (A) | 1,342 | 1,299 | 670 | 619 | ||
Variable Pay3 | Annual bonus - cash | 3,593 | 3,025 | 968 | 673 | |
Annual bonus - deferred shares | 4,072 | 2,618 | 629 | 338 | ||
LTIP | - | - | - | - | ||
Sub-total - ordinary course variable pay (B) | 7,665 | 5,643 | 1,597 | 1,011 | ||
Sub-total - single total figure, excluding legacy arrangements (A+B)3 | 9,007 | 6,942 | 2,267 | 1,630 | ||
RLTIP - Legacy Award granted in December 20214 | 8,261 | - | - | - | ||
Sub-total -legacy variable pay (C) | 8,261 | - | - | - | ||
Total Variable remuneration, including legacy arrangements (B+C) | 15,926 | 5,643 | 1,597 | 1,011 | ||
Single total figure, including legacy arrangements (A+B+C) | 17,268 | 6,942 | 2,267 | 1,630 | ||
Financial measure | Weighting | Threshold (25% of max) | Target (50% of max) | Maximum (100% of max) | 2025 outcome | % achieved | Bonus outcome after weighting (% of max) |
Adjusted Profit Before Tax | 37.5% | $310.5m | $345.0m | $379.5m | $418.1m | 100 | 100 |
Adjusted Earnings Per Share1 | 37.5% | $3.07 | $3.41 | $3.75 | $3.99 | 100 | 100 |
Target | Weighting1 (% of bonus) | Assessment |
Lead the execution of our growth plan for 2025 to 2027 and beyond, including overseeing the evaluation, execution and integration of acquisitions. Continue to promote and incentivise cross selling efforts across the firm to maximise value from clients. | 7% | Continued to drive the business forward, delivering growth across all relevant metrics. Successful acquisitions completed including Aarna, Hamilton Court, Darton, Agrinvest and Winterflood. Appointed a new lead for cross- selling initiative. Achieved a 40% revenue growth in multi- segment clients which is attributable to active cross-sell. |
Ensure Marex operates within the board’s approved risk appetite, complies with legal and regulatory obligations and maintains a strong control framework and operational resilience. Continue to ensure open, transparent and constructive relationships with all Marex’s regulators. | 6% | Oversees a strong control framework and operational resilience. Market risk well inside Board Risk Appetite and “loss days” consistent with history. Credit risk within Appetite; limited realised losses. Issued $500 million of notes in May which was 2.6 times oversubscribed. Maintained investment grade rating through positive interactions with the agencies. |
Build and oversee a strong organisational and people plan commensurate with a firm of Marex’s size and complexity. Grow executive bench and encourage firm- wide cooperation. | 6% | Focussed on developing senior executives to be effective in a larger organization and manage bigger businesses across complex markets. Made some significant senior hires during 2025 who have made immediate impact. |
Set tone from the top to promote a positive culture throughout the firm which encourages and rewards high standards of behaviour and cooperation. Promote positive employee engagement and diversify our employee base. Continue to develop an effective ESG strategy. | 6% | Increased graduate programme, launched the Women’s Affinity Network, and strengthened partnership with Future Frontiers (UK education charity). Steady progress in strengthening the organisation – with voluntary attrition down and an improved Net Promoter score achieved in the Engagement Survey. Maintained employee engagement through regular Town Halls. |
Total for Strategic Measures | 22/25 |
Target | Weighting1 (% of bonus) | Assessment |
Move firm towards a controls-based audit for 2026 and ensure that the firm is “SOX” compliant by the end of 2025. | 7% | Successfully led resources across the firm to address historical control processes and drove the firm towards “SOX” compliance whilst embedding a new control structure across key areas of the firm. |
Increase engagement with existing and potential investors to facilitate leadership on all financial matters as well as support the CEO in communicating the firm’s strategic objectives. | 6% | Delivers the financial updates on Investor calls and town halls. Continues to develop direct interaction with investors. |
Ensure Marex operates within the board’s approved risk appetite, complies with legal and regulatory obligations and maintains a strong control framework and operational resilience. | 6% | Successfully recruited experienced resources to develop a bigger and more talented Finance team, with a strong financial reporting framework at the core of the finance operation. Successfully engages with Deloitte to manage the audit process. |
Set tone from the top to promote a positive culture throughout the firm which encourages and rewards high standards of behaviour and cooperation. Continue to develop an effective ESG strategy as Chair of the Sustainability Committee. | 6% | Chaired the sustainability committee and continues to actively lead the team to move towards our stated goals. The Finance team are positive around management support and the team culture fostered within Finance. |
Total for Strategic Measures | 22/25 |
Ian Lowitt | Rob Irvin | |
Percentage of maximum annual bonus awarded | 97% | 97% |
Quantum of award – total | $7,664,707 | $1,596,814 |
Quantum of award – paid in cash | $3,592,667 | $967,966 |
Quantum of awards – deferred into share awards | $4,072,040 | $628,848 |
Financial measure | Weighting | Threshold (20% of max) | Straight Line Apportionment | Maximum (100% of max) |
Growth in Adjusted Operating Profit After Tax | 100% | average of 5% pa over the Performance Period | more than 5% and less than 12% over the Performance Period | average of 12% pa over the Performance Period |
Date of grant | Type of award1 | Form of award | Number of shares subject to award2 | Shares receivable if minimum performance is achieved (%)3 | Face value of award at award date | End of period for which performance targets need to be achieved | Vesting schedule | |
Ian Lowitt | March 11, 2025 | Annual LTIP | Performance -based conditional award | 69,475 | 43% | $2,207,221 | 31 December 2027 | Awards will vest in a single tranche on the third anniversary of grant (or the date on which performance conditions are assessed, if later). |
March 11, 2025 | DBP | Service- based conditional award | 82,403 | N/A | $2,617,964 | N/A | Awards will vest in three equal tranches on the first, second and third anniversary of grant (or the date on which the audited accounts are published in each of those years if later). | |
Rob Irvin | March 11, 2025 | Annual LTIP | Performance -based conditional award | 24,316 | 43% | $772,519 | 31 December 2027 | Awards will vest in a single tranche on the third anniversary of grant (or the date on which performance conditions are assessed, if later). |
March 11, 2025 | DBP | Service- based conditional award | 10,625 | N/A | $337,562 | N/A | Awards vest in three equal tranches on the first, second and third anniversary of grant (or the date on which the audited accounts are published in each of those years if later). |
Name | Base fees1 | Other fees2 | Equity awards3 | Total |
Robert Pickering | $395,088 | $3,667 | $120,036 | $518,791 |
Linda Myers | $111,942 | $49,760 | $120,036 | $281,738 |
Sarah Ing | $111,942 | $49,760 | $120,036 | $281,738 |
Konstantin Graf von Schweinitz | $111,942 | $36,591 | $120,036 | $268,569 |
Roger Nagioff4 | $41,189 | $1,869 | $- | $43,058 |
Henry Richards5 | $37,314 | $1,688 | $- | $39,002 |
John Pietrowicz | $111,942 | $16,836 | $120,036 | $248,814 |
Name | Base fees1 | Other fees2 | Equity awards6 | Total |
Robert Pickering | $357,208 | $- | $217,804 | $575,012 |
Linda Myers | $100,765 | $44,784 | $220,330 | $365,879 |
Sarah Ing | $100,765 | $47,450 | $219,067 | $367,282 |
Konstantin Graf von Schweinitz | $100,765 | $37,320 | $200,943 | $339,028 |
Roger Nagioff4 | $74,599 | $- | $110,088 | $184,687 |
Henry Richards5 | $74,599 | $- | $99,448 | $174,047 |
Madelyn Antoncic7 | $95,876 | $26,009 | $24,144 | $146,029 |
John Pietrowicz | $74,590 | $8,776 | $211,742 | $295,108 |
Date of grant | Type of award | Form of award | Number of shares subject to award | Face value of award at award date | Vesting schedule | |
Robert Pickering | 5/30/2025 | Annual Grant | Nil-cost conditional share award | 2,787 | $120,036 | Awards vest in a single tranche on the first anniversary of the grant date. |
Linda Myers | 5/30/2025 | Annual Grant | Nil-cost conditional share award | 2,787 | $120,036 | Awards vest in a single tranche on the first anniversary of the grant date. |
Sarah Ing | 5/30/2025 | Annual Grant | Nil-cost conditional share award | 2,787 | $120,036 | Awards vest in a single tranche on the first anniversary of the grant date. |
Konstantin Graf von Schweinitz | 5/30/2025 | Annual Grant | Nil-cost conditional share award | 2,787 | $120,036 | Awards vest in a single tranche on the first anniversary of the grant date. |
John Pietrowicz | 5/30/2025 | Annual Grant | Nil-cost conditional share award | 2,787 | $120,036 | Awards vest in a single tranche on the first anniversary of the grant date. |
Interests in shares excluding outstanding scheme interests | Outstanding scheme interests | Total of all share interests and outstanding scheme interests | ||||
Unvested scheme interests (not subject to performance measures) | Unvested scheme interests (subject to performance measures) | Vested but unexercised scheme interests | Total shares subject to outstanding scheme interests | |||
Ian Lowitt | 2,615,016 | 203,920 | 246,890 | n/a | 450,810 | 3,065,826 |
Rob Irvin | 3,785 | 59,713 | 51,997 | n/a | 111,710 | 115,495 |
Robert Pickering | 26,909 | 2,787 | n/a | n/a | 2,787 | 29,696 |
Sarah Ing | 7,348 | 2,787 | n/a | n/a | 2,787 | 10,135 |
Konstantin Graf von Schweinitz | 21,308 | 2,787 | n/a | n/a | 2,787 | 24,095 |
Linda Myers | 19,472 | 2,787 | n/a | n/a | 2,787 | 22,259 |
Madelyn Antoncic | 0 | — | n/a | n/a | — | — |
John Pietrowicz | 19,472 | 2,787 | n/a | n/a | 2,787 | 22,259 |
Henry Richards | 0 | — | n/a | n/a | — | — |
Roger Nagioff | 0 | — | n/a | n/a | — | — |
Description | Type | Vesting dates | At 1 January 2025 | Changes during the year | At 31 December 2025 | |||
Granted | Lapsed | Released | ||||||
Ian Lowitt | Legacy Retention LTIP | Conditional award | 3/31/2025 | 245,811 | - | - | 245,811 | - |
Ian Lowitt | Legacy 2022 Annual LTIP | Conditional award | 9/27/2026 | 77,843 | - | - | - | 77,843 |
Ian Lowitt | Legacy 2023 Annual LTIP | Conditional award | 6/5/2027 | 99,572 | - | - | - | 99,572 |
Ian Lowitt | 2024 Annual LTIP | Conditional award | 11/3/2028 | - | 69,475 | - | - | 69,475 |
Ian Lowitt | Legacy Conditional Award | Conditional award | 4/28/2025 | 142,709 | - | - | 142,709 | - |
Ian Lowitt | 2021 Legacy Deferred Bonus Plan | Conditional award | 31/3/2025 | 8,702 | - | - | 8,702 | - |
Ian Lowitt | 2022 Legacy Deferred Bonus Plan | Conditional award | 5/4/2025 5/4/2026 | 92,947 | - | - | 46,473 | 46,474 |
Ian Lowitt | 2023 DBP | Conditional award | 5/17/2025 5/17/2026 5/17/2027 | 112,564 | - | - | 37,521 | 75,043 |
Ian Lowitt | 2024 DBP | Conditional award | 3/11/2026 3/11/2027 3/11/2028 | - | 82,403 | - | - | 82,403 |
Rob Irvin | Legacy 2023 Annual LTIP | Conditional award | 6/5/2027 | 27,681 | - | - | - | 27,681 |
Rob Irvin | 2024 Retention LTIP | Conditional award | 6/6/2027 | 39,473 | - | - | - | 39,473 |
Rob Irvin | 2024 Annual LTIP | Conditional award | 11/3/2028 | 24,316 | - | - | - | 24,316 |
Rob Irvin | 2022 Legacy Deferred Bonus Plan | Conditional award | 5/4/2025 5/4/2026 | 9,346 | - | - | 4,673 | 4,673 |
Rob Irvin | 2023 DBP | Conditional award | 5/17/2025 5/17/2026 5/17/2027 | 7,412 | - | - | 2,470 | 4,942 |
Rob Irvin | 2024 DBP | Conditional award | 3/11/2026 3/11/2027 3/11/2028 | - | 10,625 | - | - | 10,625 |
Robert Pickering | 2024 NED Awards | Conditional award | 11/8/2025 | 6,315 | - | 6,315 | - | |
Robert Pickering | 2025 NED Awards | Conditional award | 30/5/2026 | - | 2,787 | - | - | 2,787 |
Sarah Ing | 2024 NED Awards | Conditional award | 11/8/2025 | 6,315 | - | 6,315 | - | |
Sarah Ing | 2025 NED Awards | Conditional award | 30/5/2026 | - | 2,787 | - | 2,787 | |
Konstantin Graf von Schweinitz | 2024 NED Awards | Conditional award | 11/8/2025 | 6,315 | - | - | 6,315 | - |
Konstantin Graf von Schweinitz | 2025 NED Awards | Conditional award | 30/5/2026 | - | 2,787 | - | - | 2,787 |
Linda Myers | 2024 NED Awards | Conditional award | 11/8/2025 | 6,315 | - | - | 6,315 | - |
Linda Myers | 2025 NED Awards | Conditional award | 30/5/2026 | — | 2,787 | - | - | 2,787 |
Madelyn Antoncic | 2024 NED Awards | Conditional award | 11/8/2025 | 6,315 | - | 5,623 | 692 | - |
John Pietrowicz | 2024 NED Awards | Conditional award | 11/8/2025 | 6,315 | - | - | 6,315 | - |
John Pietrowicz | 2025 NED Awards | Conditional award | 30/5/2026 | — | 2,787 | - | - | 2,787 |
Henry Richards | 2024 NED Awards | Conditional award | 11/8/2025 | 6,315 | - | 3,408 | 2,907 | - |
Roger Nagioff | 2024 NED Awards | Conditional award | 11/8/2025 | 6,315 | - | 3,097 | 3,218 | - |
Director | Number of eligible shares as at 31 December 20251 | Value of shares held as at 31 December 20252 | Shareholding as % of base salary as at 31 December 2025 | Shareholding requirement (% of salary) |
Ian Lowitt | 2,651,042 | $101,693,971 | 7722% | 300% |
Rob Irvin | 11,358 | $435,692 | 66% | 200% |
2025 | 20241 | |
CEO single figure of remuneration | $17.268m | $6.942m |
Annual Bonus as a % of maximum opportunity (%) | 97% | 98% |
LTIP award as a % of maximum opportunity (%) | 100% | 100% |

Change in salary / NED fees | Change in benefits | Change in bonus | |||||||||||||
2024 to 2025 | 2023 to 2024 | 2022 to 2023 | 2021 to 2022 | 2020 to 2021 | 2024 to 2025 | 2023 to 2024 | 2022 to 2023 | 2021 to 2022 | 2020 to 2021 | 2024 to 2025 | 2023 to 2024 | 2022 to 2023 | 2021 to 2022 | 2020 to 2021 | |
Ian Lowitt11 | -% | -% | 33% | (63)% | -% | 26% | (20)% | 7% | (6)% | (5)% | 32% | 14% | 6% | 195% | 36% |
Rob Irvin2,11 | 5% | 19% | n/a | n/a | n/a | -% | -% | n/a | n/a | n/a | 54% | 41% | n/a | n/a | n/a |
Robert Pickering3 | 7% | 103% | 38% | -% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Linda Myers4 | 5% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sarah Ing5 | 4% | 14% | 1% | -% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Konstantin Graf von Schweinitz6 | 2% | 8% | -% | -% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Roger Nagioff7 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Henry Richards8 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Madelyn Antoncic9 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
John Pietrowicz10 | 46% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Year | Method | 25th percentile pay ratio | Total pay and benefits (25th percentile) | Salary component of total pay and benefits (25th percentile) | Median pay ratio | Total pay and benefits (50th percentile | Salary component of total pay and benefits (50th percentile) | 75th percentile pay ratio | Total pay and benefits (75th percentile) | Salary component of total pay and benefits (75th percentile) |
2025 | A | 135:1 | $128,107 | $79,020 | 87:1 | $198,637 | $118,530 | 37:1 | $460,555 | $171,210 |
2024 | A | 67:1 | $102,683 | $76,773 | 35:1 | $200,864 | $108,761 | 14:1 | $381,880 | $159,943 |
Current Year | 2024 | |
Employee remuneration (USD m) | 1,234.2 | 971.1 |
Distributions to shareholders (USD m) | 55.5 | 77.1 |
Executive Director | Base salary at 1st Jan 2025 ($) | Base salary at 1st Jan 2026 ($) | % change |
Ian Lowitt | $1,317,000 | $1,317,000 | —% |
Rob Irvin | $658,000 | $698,000 | 6% |
Element | Weighting | |
Financial Measures | 75% | |
Adjusted Operating PBT | 37.5% | |
EPS | 37.5% | |
Strategic Measures | 25% | |
Total | 100% |
Financial measure | Weighting | Threshold (50% of max) | Straight Line Apportionment | Maximum (100% of max) |
Growth in Adjusted Operating Profit Before Tax | 50% | average of 5% pa over the Performance Period | more than 5% and less than 10% over the Performance Period | average of 10% pa over the Performance Period |
Growth in Adjusted EPS | 50% | average of 5% pa over the Performance Period | more than 5% and less than 8% over the Performance Period | average of 8% pa over the Performance Period |
Non-Executive Director | Base Fee1 at 1st June 2025 ($) | Base Fee at 1st Jan 2026 ($) | % change |
Robert Pickering | $383,865 | $383,865 | —% |
Linda Myers2 3 | $108,761 | $108,761 | —% |
Sarah Ing2 | $108,761 | $108,761 | —% |
Konstantin Graf von Schweinitz2 | $108,761 | $108,761 | —% |
John Pietrowicz3 | $108,761 | $108,761 | —% |
Member | Attendance1 |
Linda Myers | 4/4 |
Robert Pickering | 4/4 |
Sarah Ing | 4/4 |
Roger Nagioff | 0/1 |
Henry Richards | 1/1 |
Directors' Remuneration Policy 2025 AGM | Directors' Remuneration Report 2025 AGM | |
Percentage for | 92.41% | 99.41% |
Votes for | 48,635,366 | 52,323,543 |
Percentage against | 7.58% | 0.58% |
Votes against | 3,992,555 | 307,288 |
Total votes cast excluding votes withheld | 52,627,921 | 52,630,831 |
Votes withheld1 | 7,950 | 5,040 |
Total votes cast including votes withheld | 52,635,871 | 52,635,871 |
Year Ended December 31, | |||
2025 | 2024 | 2023 | |
Employees by geography | |||
United Kingdom ............................................................................... | 1,631 | 1,095 | 956 |
Europe ............................................................................................... | 282 | 218 | 196 |
North America .................................................................................. | 756 | 709 | 688 |
APAC ................................................................................................. | 229 | 200 | 171 |
Other Regions(1) ............................................................................... | 211 | 118 | 63 |
Total ................................................................................................... | 3,109 | 2,340 | 2,074 |
Employees by role | |||
Front-office employees ................................................................... | 1,506 | 1,241 | 1,175 |
Control and support employees .................................................... | 1,603 | 1,099 | 899 |
Total ................................................................................................... | 3,109 | 2,340 | 2,074 |
Name of beneficial owner | Number | %(4) |
5% or Greater Shareholders | ||
Amphitryon Limited(1) ................................................................................................. | 7,160,826 | 9.98 |
MASP Investor Limited Partnership(2) ..................................................................... | 5,024,604 | 7.00 |
Directors and Executive Officers(3) | ||
Ian Lowitt ..................................................................................................................... | 2,642,483 | 3.68 |
Robert Irvin ................................................................................................................. | 7,326 | * |
Paolo Tonucci ............................................................................................................. | 1,125,908 | 1.57 |
Simon van den Born .................................................................................................. | 1,171,570 | 1.63 |
Thomas Texier ............................................................................................................ | 76,000 | * |
Nilesh Jethwa ............................................................................................................. | 99,747 | * |
Robert Pickering ........................................................................................................ | 26,909 | * |
Konstantin Graf von Schweinitz .............................................................................. | 21,308 | * |
Sarah Ing ..................................................................................................................... | 7,348 | * |
Linda Myers ................................................................................................................ | 19,472 | * |
John W. Pietrowicz .................................................................................................... | 19,472 | * |
All executive officers and directors as a group (11 persons) ..................... | 5,217,543 | 7.27 |
December 31, 2025 | December 31, 2024 | ||
Business | VaR | VaR | Additional risk metrics monitored |
European Emerging Bonds | less than $0.5m | Stress, GMV, DV01, CS01, Aged Inventory | |
Equities Market Making | less than $0.5m | less than $0.5m | Gross long/short and single name equity delta, FX delta |
FX Frontier | less than $0.5m | less than $0.5m | FX delta by currency, tenor and book |
FX OTC | less than $0.5m | less than $0.5m | FX delta by currency, tenor and book |
Interest Rate Swaps | less than $0.5m | less than $0.5m | PV01 by currency and tenor |
U.S. Emerging Corporate Bond | less than $0.5m | less than $0.5m | Stress, GMV, DV01, CS01, Aged Inventory |
U.S. Equity Securities Lending | less than $0.5m | less than $0.5m | Stress, GMV, DV01 |
U.S. Fixed Income Corporate Bond | less than $0.5m | less than $0.5m | Stress, GMV, DV01, CS01, Aged Inventory |
U.S. Fixed Income Financing Services | less than $0.5m | less than $0.5m | Stress, GMV, DV01 |
Marex Fund (Formerly Volatility Performance Fund) | less than $0.5m | less than $0.5m | Equity delta and vega, tenor, FX delta |
Winterflood- Equities Market Making | less than $0.5m | Gross long/short and single name equity delta, FX delta, DV01 |
December 31, 2025 | December 31, 2024 | ||
Business | VaR | VaR | Additional risk metrics monitored |
Agricultural | less than $1.0m | less than $3.0m | Outright Delta, Delta spreads, Vega |
Metals | less than $2.0m | less than $2.0m | Outright Delta, Delta spreads, Vega |
CSC Commodities | less than $0.5m | less than $0.5m | Outright Delta, Delta spreads, Vega |
Energy Market Making | less than $1.5m | less than $1.0m | Outright Delta, Delta spreads, Vega, Stress |
2025 | 2024 | |
$m | $m | |
Audit Fees ............................................................................................................................... | 14.5 | 10.9 |
Audit Related Fees ................................................................................................................ | 1.1 | 2.1 |
All Other Fees ........................................................................................................................ | 0.0 | 0.0 |
Total ........................................................................................................................................ | 15.6 | 13.0 |
Incorporation by Reference | ||||||
Exhibit No. | Description | Form | File No. | Exhibit No. | Filing Date | Filed / Furnished |
1.1 | Amended and Restated Articles of Association of Marex Group plc | F-1 | 333-278231 | 3.1 | April 26, 2024 | |
2.1 | Description of Securities | * | ||||
2.2 | Shareholders’ Agreement by and among the Registrant and certain shareholders of the Registrant | 20-F | 001-42020 | 2.2 | March 21, 2025 | |
2.3 | Registration Rights Agreement by and among the Registrant and certain shareholders of the Registrant | 20-F | 001-42020 | 2.3 | March 21, 2025 | |
2.4 | Senior Indenture dated as of October 15, 2024 between Marex Group plc and Citibank, N.A., as trustee | F-1 | 333-282656 | 4.1 | October 22, 2024 | |
2.5 | Form of Master Global Note (included in 2.4 above) | F-1 | 333-282656 | 4.2 | October 22, 2024 | |
2.6 | First Supplemental Indenture dated as of November 4, 2024 to the Senior Indenture dated as of October 15, 2024 between Marex Group plc and Citibank, N.A., as trustee | 6-K | 001-42020 | 4.2 | November 4, 2024 | |
2.7 | Second Supplemental Indenture dated as of May 8, 2025 to the Senior Indenture dated as of October 15, 2024 between Marex Group plc and Citibank, N.A., as trustee | 6-K | 001-42020 | 4.2 | May 8, 2025 | |
2.8 | Subordinated Indenture dated as May 1, 2025 between Marex Group plc and Citibank N.A., as trustee | F-3 | 333-286884 | 4.4 | May 1, 2025 | |
2.9 | Contingent Capital Securities Indenture dated as May 1, 2025 between Marex Group plc and Citibank N.A., as trustee | F-3 | 333-286884 | 4.5 | May 1, 2025 | |
2.10 | Senior Indenture dated as of August 4, 2025 between Marex Group plc and The Bank of New York Mellon as trustee | F-3 | 333-289203 | 4.1 | August 4, 2025 | |
2.11 | Form of Master Global Security (included in 2.10 above) | F-3 | 333-289203 | 4.2 | August 4, 2025 | |
4.1† | Form of Deed Indemnity | F-1 | 333-278231 | 10.3 | April 15, 2024 | |
4.2† | Marex Group plc Retention Long Term Incentive Plan | F-1 | 333-278231 | 10.4 | April 15, 2024 | |
4.3† | Marex Group plc 2021 Deferred Bonus Plan | F-1 | 333-278231 | 10.5 | April 15, 2024 | |
4.4† | Marex Group plc 2022 Deferred Bonus Plan | F-1 | 333-278231 | 10.6 | April 15, 2024 | |
4.5† | Long-Term Incentive Plan | F-1 | 333-278231 | 10.7 | April 15, 2024 | |
4.6† | Marex Group plc Global Omnibus Plan | S-8 | 333-278953 | 99.5 | April 26, 2024 | |
4.7† | Marex Group Limited 2007 Employee Share Purchase Plan, as amended on April 10, 2024 | F-1 | 333-278231 | 10.10 | April 15, 2024 | |
4.8 | Form of Company Lock-up Agreement | F-1 | 333-278231 | 10.11 | April 15, 2024 | |
4.9† | Marex Group plc Employee Share Purchase Plan | S-8 | 333-278953 | 99.6 | April 26, 2024 | |
8.1 | List of Subsidiaries. | * | ||||
11.1 | Insider Trading Policy | 20-F | 001-42020 | 11.1 | March 21, 2025 | |
12.1 | Principal Executive Officer Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | * | ||||
12.2 | Principal Financial Officer Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | * | ||||
13.1 | Principal Executive Officer Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ** | ||||
13.2 | Principal Financial Officer Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ** | ||||
15.1 | Consent of Deloitte LLP, an independent registered public accounting firm. | * | ||||
97.1 | Policy for Recovery of Erroneously Awarded Compensation | * | ||||
101.INS | Inline XBRL Instance Document – the instance document appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | * | ||||
101.SCH | Inline XBRL Taxonomy Extension Schema Document. | * | ||||
101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | * | ||||
101.DEF | Inline XBRL Taxonomy Definition Linkbase Document. | * | ||||
101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. | * | ||||
101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | * | ||||
104 | Cover Page Interactive Data File (formatted as Inline XBRL and | * |
MAREX GROUP PLC | ||
Date: March 25, 2026 | By: | /s/ Ian Lowitt |
Name: | Ian Lowitt | |
Title: | Chief Executive Officer | |
Date: March 25, 2026 | By: | /s/ Rob Irvin |
Name: | Rob Irvin | |
Title: | Chief Financial Officer | |
Date: March 25, 2026 | By: | /s/ Ian Lowitt |
Chief Executive Officer | ||
(Principal Executive Officer) |
Date: March 25, 2026 | By: | /s/ Rob Irvin |
Chief Financial Officer | ||
(Principal Financial Officer) |
Date: March 25, 2026 | By: | /s/ Ian Lowitt |
Chief Executive Officer | ||
(Principal Executive Officer) |
Date: March 25, 2026 | By: | /s/ Rob Irvin |
President and Chief Financial Officer | ||
(Principal Financial Officer) |
Financial Statements | |
Report of Independent Registered Public Accounting Firm - Deloitte LLP (PCAOB ID No. | 199 |
Consolidated Income Statement | 201 |
Consolidated Statement of Comprehensive Income | 202 |
Consolidated Statement of Financial Position | 203 |
Consolidated Statement of the Changes in Equity | 205 |
Consolidated Statement of Cash Flows | 208 |
Notes to the Consolidated Financial Statements | 210 |
Company Financial Statements | 310 |
Company Statement of Financial Position | 311 |
Company Statement of Cash Flows | 312 |
Notes to the Company Financial Statements | 313 |
2025 | 2024 | 2023 | ||
Notes | $m | $m | $m | |
Commission and fee income | ||||
Commission and fee expense | ( | ( | ( | |
Net commission income | 5 | |||
Net trading income | 5 | |||
Interest income | 6 | |||
Interest expense | 6 | ( | ( | ( |
Net interest income | 6 | |||
Net physical commodities income | 5 | |||
Revenue | 5 | |||
Expenses | ||||
Compensation and benefits | 7 | ( | ( | ( |
Depreciation and amortisation | 15, 16, 37 | ( | ( | ( |
Other expenses | 8 | ( | ( | ( |
Total expenses | ( | ( | ( | |
Impairment of goodwill | 13 | ( | ||
Net recovery of/(provision) for credit losses | ( | |||
Bargain purchase gain on acquisitions | 12 | |||
Other income | ||||
Share of results in associates and joint ventures | ||||
Profit before tax from continuing operations | ||||
Tax | 10 | ( | ( | ( |
Profit after tax from continuing operations | ||||
Loss after tax from discontinued operations | 14 | ( | ||
Profit after tax | ||||
Attributable to: | ||||
Ordinary shareholders of the Group | ||||
Non-controlling interest | 12(c) | |||
Other equity holders1 | ||||
Earnings per share2 | ||||
Basic (dollars per share) | 9 | |||
Diluted (dollars per share) | 9 |
2025 | 2024 | 2023 | ||
Notes | $m | $m | $m | |
Profit after tax | ||||
Other comprehensive income | ||||
Items that may be reclassified subsequently to profit and loss: | ||||
Cash flow hedges | ||||
Fair value gain/(loss) arising on hedging instruments during the year | ( | |||
Deferred tax (charge)/credit on hedging instruments | 10 | ( | ( | |
Currency translation adjustments | ( | |||
Items that will not be recycled to profit or loss: | ||||
Change in fair value of financial liabilities designated at FVTPL due to own credit risk | ( | ( | ||
Deferred tax credit on change in fair value of financial liabilities designated at FVTPL due to own credit risk | 10 | |||
Fair value (loss)/gain on investments in equity instruments designated at FVTOCI | 17 | ( | ||
Deferred tax credit/(charge) on revaluation of investments | 10 | ( | ( | |
Other comprehensive income/(loss), net of tax | ( | ( | ||
Total comprehensive income | ||||
Attributable to: | ||||
Ordinary shareholders of the Group | ||||
Non-controlling interest | ||||
Other equity holders1 |
31 December | 31 December | ||
2025 | 2024 | ||
Notes | $m | $m | |
Assets | |||
Non-current assets | |||
Goodwill | 13 | ||
Intangible assets | 15 | ||
Property, plant and equipment | 16 | ||
Right of use asset | 37 | ||
Investments | 17 | ||
Trade and other receivables | 25 | ||
Derivative instruments | 23 | ||
Deferred tax | 10 | ||
Treasury instruments (unpledged) | 18 | ||
Treasury instruments (pledged as collateral) | 18 | ||
Total non-current assets | |||
Current assets | |||
Corporate income tax receivable | |||
Trade and other receivables | 25 | ||
Inventory | 20 | ||
Equity instruments (unpledged) | 19 | ||
Equity instruments (pledged as collateral) | 19 | ||
Derivative instruments | 23 | ||
Stock borrowing | 34 | ||
Treasury instruments (unpledged) | 18 | ||
Treasury instruments (pledged) and assets held under agreements to sell (repledged) | 18 | ||
Fixed income securities (unpledged) | 21 | ||
Fixed income securities (pledged as collateral) | 21 | ||
Reverse repurchase agreements | 24 | ||
Cash and cash equivalents | |||
Assets classified as held for sale | 14 | ||
Total current assets | |||
Total assets |
31 December | 31 December | ||
2025 | 2024 | ||
Notes | $m | $m | |
Liabilities | |||
Current liabilities | |||
Repurchase agreements | 24 | ||
Trade and other payables | 26 | ||
Stock lending | 34 | ||
Short securities | 34 | ||
Short term borrowings | 27 | ||
Lease liability | 37 | ||
Derivative instruments | 23 | ||
Corporate tax | |||
Debt securities | 22 | ||
Provisions | |||
Liabilities related to assets classified as held for sale | 14 | ||
Total current liabilities | |||
Non-current liabilities | |||
Lease liability | 37 | ||
Derivative instruments | 23 | ||
Debt securities | 22 | ||
Deferred tax liability | 10 | ||
Total non-current liabilities | |||
Total liabilities | |||
Total net assets | |||
Equity | |||
Share capital | 29 | ||
Share premium | 29 | ||
Retained earnings | |||
Own shares | 30 | ( | ( |
Other reserves | ( | ||
Total equity attributable to the ordinary shareholders of the Group | |||
Non-controlling interest | ( | ||
Additional Tier 1 capital (AT1) | 31 | ||
Total equity |
Share capital | Share premium | Retained earnings | Own Shares | Other reserves | Equity attributable to the ordinary shareholders of the Group | Non- controlling interest | Additional Tier 1 capital (AT1) | Total Equity | ||
Group | Notes | $m | $m | $m | $m | $m | $m | $m | $m | |
At 1 January 2023 | ( | ( | ||||||||
Profit after tax for the period | — | — | — | — | — | |||||
Gain on cash flow hedge | — | — | — | — | — | |||||
Deferred tax on cash flow hedge reserve | — | — | — | — | ( | ( | — | — | ( | |
Change in fair value of financial liabilities designated at FVTPL due to own credit risk | — | — | — | — | ( | ( | — | — | ( | |
Deferred tax on change in fair value of financial liabilities designated at FVTPL due to own credit risk | — | — | — | — | — | — | ||||
Deferred tax on revaluation of investments | — | — | — | — | ( | ( | — | — | ( | |
Currency translation adjustments | — | — | — | — | — | — | ||||
Total comprehensive income for the period | — | — | — | ( | — | |||||
AT1 dividends paid | 31 | — | — | — | — | — | — | — | ( | ( |
Ordinary dividends paid | 11 | — | — | ( | — | — | ( | — | — | ( |
Repurchase of own shares | — | — | — | ( | — | ( | — | — | ( | |
Share-based payments | — | — | — | — | — | — | ||||
Deferred tax on share-based payments | — | — | — | — | — | — | ||||
Share settlement (share-based payments) | — | — | ( | — | — | — | ||||
Other movements | — | — | ( | — | — | ( | — | — | ( | |
At 31 December 2023 and 1 January 2024 | ( | ( | ||||||||
Profit after tax for the period | — | — | — | — | — |
Fair value loss on hedging instruments | — | — | — | — | ( | ( | — | — | ( | |
Deferred tax on hedging instruments | — | — | — | — | — | — | ||||
Change in fair value of financial liabilities designated at FVTPL due to own credit risk | — | — | — | — | ( | ( | — | — | ( | |
Deferred tax on change in fair value of financial liabilities designated at FVTPL due to own credit risk | — | — | — | — | — | — | ||||
Gain on revaluation of investments | — | — | — | — | — | — | ||||
Deferred tax on revaluation of investments | — | — | — | — | ( | ( | — | — | ( | |
Currency translation adjustments | — | — | — | — | ( | ( | — | — | ( | |
Total comprehensive income for the period | — | — | — | ( | — | |||||
AT1 dividends paid | 31 | — | — | — | — | — | — | — | ( | ( |
Ordinary dividends paid | 11 | — | — | ( | — | — | ( | — | — | ( |
Share premium | — | — | — | — | — | — | ||||
Repurchase of own shares | — | — | — | ( | — | ( | — | — | ( | |
Fair value of the cash settlement option on the growth shares | — | — | — | — | — | — | ||||
Share-based payments | — | — | — | — | — | — | ||||
Deferred tax on share based payments | — | — | — | — | — | — | ||||
Current tax on share based payments | — | — | — | — | — | — | ||||
Share settlement of share-based awards | — | — | ( | — | — | — | ||||
Other movements | — | — | — | ( | — | — | ||||
At 31 December 2024 and 1 January 2025 | ( | ( | ||||||||
Profit after tax for the period | — | — | — | — | ||||||
Fair value gain on hedging instruments | — | — | — | — | — | — | ||||
Deferred tax on hedging instruments | — | — | — | — | ( | ( | — | — | ( |
Change in fair value of financial liabilities designated at FVTPL due to own credit risk | — | — | — | — | — | — | ||||
Deferred tax on change in fair value of financial liabilities designated at FVTPL due to own credit risk | — | — | — | — | — | — | ||||
Loss on revaluation of investments | — | — | — | — | ( | ( | — | — | ( | |
Deferred tax on revaluation of investments | — | — | — | — | — | — | ||||
Currency translation adjustments | — | — | — | — | — | — | ||||
Total comprehensive income for the period | — | — | — | |||||||
AT1 dividends paid | 31 | — | — | — | — | — | — | — | ( | ( |
Ordinary dividends paid | 11 | — | — | ( | — | — | ( | — | — | ( |
Share premium | — | — | ( | — | — | — | ||||
Share-based payments | — | — | — | — | — | — | ||||
Deferred tax on share based payments | — | — | — | — | ( | ( | — | — | ( | |
Current tax on share based payments | — | — | — | — | — | — | ||||
Acquisition of own shares | — | — | — | ( | — | ( | — | — | ( | |
Share settlement of share-based awards | — | — | ( | — | — | — | ||||
Transactions with minority interest holders | — | — | ( | — | — | ( | ( | — | ( | |
At 31 December 2025 | ( | ( |
2025 | 2024 | 2023 | ||
Notes | $m | $m | $m | |
Reconciliation of profit before tax to net cash flows from operating activities | ||||
Profit before tax from continuing operations | ||||
Adjustments for non-cash items | ||||
Depreciation, amortization & impairment of property, plant & equipment, right-of-use asset and intangibles | 15, 16, 37 | |||
Bargain purchase gain on acquisitions | 12 | ( | ( | |
Impairment of goodwill | ||||
Net (recovery)/provision for credit losses | ( | ( | ||
Share-based compensation expense | 7 | |||
Share of results in associates and joint ventures | ( | |||
Other non-cash movements including exchange rate movements | 12, 13, 16, 37 | ( | ( | |
Changes in operating assets and liabilities | ||||
(Increase)/decrease in trade and other receivables | ( | ( | ||
Increase/(decrease) in trade and other payables | ( | |||
(Increase)/decrease in fixed income securities | 21 | ( | ( | |
(Increase) in treasury instruments | 18 | ( | ( | ( |
(Decrease)/Increase in net stock borrowing and lending | 34 | ( | ||
(Increase) in equity instruments | 19 | ( | ( | ( |
Increase/ (decrease) in net repurchase and reverse repurchase agreements | 24 | ( | ( | |
Net decrease/(increase) in derivative instruments | 23 | ( | ( | |
Net increase in debt securities1 | 22 | |||
Net increase/(repayment) of borrowings | 27 | ( | ||
(Increase)/decrease in inventory | 20 | ( | ( | |
Corporation tax paid | ( | ( | ( | |
Net cash inflow from operating activities |
2025 | 2024 | 2023 | ||
Notes | $m | $m | $m | |
Investing activities | ||||
Redemption of investment in associate | ||||
Acquisition of businesses, net of cash acquired | 12 | ( | ( | ( |
Payment of contingent consideration | ( | |||
Purchase of investments | 17 | ( | ( | |
Proceeds from sale of investments | 17 | |||
Purchase of intangible assets | 15 | ( | ( | ( |
Purchase of property, plant and equipment | 16 | ( | ( | ( |
Net cash used in investing activities | ( | ( | ( | |
Financing activities | ||||
Proceeds from issuance of ordinary shares | 29 | |||
Issuance costs of ordinary shares | 29 | ( | ||
Repayment of debt securities | 22 | ( | ||
Purchase of own shares | 30 | ( | ( | ( |
Dividends paid | 11, 31 | ( | ( | ( |
Lease incentive received | ||||
Payment of lease liabilities | 37 | ( | ( | ( |
Net cash used in financing activities | ( | ( | ( | |
Net increase in cash and cash equivalents including cash within assets held for sale | ||||
Less: Net increase in cash within assets held for sale | 14 | ( | ||
Net increase in cash and cash equivalents | ||||
Cash and cash equivalents | ||||
Cash and cash equivalents at 1 January | ||||
Increase in cash | ||||
Effect of foreign exchange rate changes | ( | |||
Cash and cash equivalents at 31 December 1 |
Clearing2 | Agency and Execution3 | Market Making4 | Hedging and Investment Solutions5 | Corporate6 | Total | ||||||
$m | $m | $m | $m | $m | $m | ||||||
Commission and fee income | |||||||||||
Commission and fee expense | ( | ( | ( | ( | |||||||
Net commission income/(expense) | |||||||||||
Net trading income | |||||||||||
Interest income / (expense) | ( | ||||||||||
Inter-segmental funding allocations1 | ( | ( | ( | ( | |||||||
Net interest income/(expense) | ( | ( | |||||||||
Net physical commodities income | |||||||||||
Revenue | |||||||||||
Adjusted profit/(loss) before tax | ( | ||||||||||
Other segment information | |||||||||||
Depreciation and amortisation | ( | ( | ( | ( | ( | ( | |||||
Compensation and benefits | ( | ( | ( | ( | ( | ( |
Clearing | Agency and Execution | Market Making | Hedging and Investment Solutions | Corporate | Total | ||||||
$m | $m | $m | $m | $m | $m | ||||||
Commission and fee income | |||||||||||
Commission and fee expense | ( | ( | ( | ( | |||||||
Net commission income/(expense) | — | ( | — | — | — | ||||||
Net trading income | |||||||||||
Interest income / (expense) | ( | ||||||||||
Inter-segmental funding allocations1 | ( | ( | ( | ( | |||||||
Net interest income/(expense) | ( | ( | |||||||||
Net physical commodities income | |||||||||||
Revenue | |||||||||||
Adjusted profit/(loss) before tax | ( | ||||||||||
Other segment information | |||||||||||
Depreciation and amortisation | ( | ( | ( | ( | ( | ( | |||||
Compensation and benefits | ( | ( | ( | ( | ( | ( |
Clearing | Agency and Execution | Market Making | Hedging and Investment Solutions | Corporate | Total | ||||||
$m | $m | $m | $m | $m | $m | ||||||
Commission and fee income | |||||||||||
Commission and fee expense | ( | ( | ( | ( | |||||||
Net commission income/(expense) | ( | ||||||||||
Net trading income | ( | ||||||||||
Interest income / (expense) | ( | ( | |||||||||
Intersegmental funding allocations1 | ( | ( | ( | ( | |||||||
Net interest income / (expense) | ( | ( | |||||||||
Net physical commodities income | |||||||||||
Revenue | — | — | — | — | |||||||
Adjusted profit/(loss) before tax | ( | ||||||||||
Other segment information | |||||||||||
Depreciation and amortisation | ( | ( | ( | ( | ( | ( | |||||
Compensation and benefits | ( | ( | ( | ( | ( | ( |
2025 | 2024 | 2023 | |
$m | $m | $m | |
Total segments adjusted profit before tax | |||
Goodwill impairment charges1 | ( | ||
Bargain purchase gain2 | |||
Amortization of acquired brands and customer lists3 | ( | ( | ( |
Activities relating to shareholders4 | ( | ( | |
Employer tax on vesting of the growth shares5 | ( | ||
Owner fees6 | ( | ( | ( |
IPO preparation costs7 | ( | ( | |
Fair value of the cash settlement option on the growth shares8 | ( | ||
Public offering of ordinary shares9 | ( | ( | |
Acquisition costs10 | ( | ( | |
Profit before tax from continuing operations |
Revenue | Total Assets1 | |||||
2025 | 2024 | 2023 | 2025 | 2024 | ||
$m | $m | $m | $m | $m | ||
United Kingdom | ||||||
United States | ||||||
Rest of the world | ||||||
Total | ||||||
2025 | 2024 | 2023 | |||||||||
Amortized Cost | FVTPL | Total | Amortized Cost | FVTPL | Total | Amortised Cost | FVTPL | Total | |||
$m | $m | $m | $m | $m | $m | $m | $m | $m | |||
Interest Income | |||||||||||
Financial institutions1 | |||||||||||
Exchanges2 | |||||||||||
Securities3 | |||||||||||
Clients4 | |||||||||||
Interest expense | |||||||||||
Clients5 | ( | ( | ( | ( | ( | ( | ( | ( | |||
Borrowings and debt issued6 | ( | ( | ( | ( | ( | ( | ( | ( | ( | ||
Exchanges7 | ( | ( | ( | ( | ( | ( | |||||
Securities8 | ( | ( | ( | ( | ( | ( | |||||
Lease interest expense | ( | ( | ( | ( | ( | ( | |||||
( | ( | ( | ( | ( | ( | ( | ( | ( | |||
Net interest income | ( | ( | ( | ||||||||
2025 | 2024 | 2023 | |||
$m | $m | $m | |||
Wages and salaries | |||||
Share-based compensation expense | |||||
Employer’s national insurance contributions and similar taxes | |||||
Short-term monetary benefits | |||||
Defined contribution pension cost | |||||
Apprenticeship levy | |||||
Redundancy payments | |||||
Total staff costs |
2025 | 2024 | 2023 | |||
$m | $m | $m | |||
Professional fees | |||||
Non-trading technology and support | |||||
Trading systems and market data | |||||
Occupancy and equipment rental | |||||
Travel and business development | |||||
Communications | |||||
Bank fees | |||||
Owner fees | |||||
VAT (irrecoverable) | |||||
Other | |||||
2025 | 2024 | 2023 | |
Profit before tax ($m)1 | |||
Tax ($m) | ( | ( | ( |
Profit after tax ($m) | |||
AT1 dividends paid ($m) | ( | ( | ( |
Non-controlling interest | ( | ||
Profit attributable to ordinary shareholders of the Group ($m) | |||
Weighted average number of ordinary shares during the year | |||
Basic earnings per share ($) | |||
Weighted average number of ordinary shares for basic EPS | |||
Effect of dilution from: | |||
Share schemes | |||
Weighted average number of ordinary shares adjusted for the effect of dilution | |||
Diluted earnings per share ($) |
2025 | 2024 | 2023 | |||
$m | $m | $m | |||
Current tax | |||||
UK corporation tax on profit for the year | |||||
Foreign corporation tax on profit for the year | |||||
Total UK and Foreign corporation tax | |||||
Adjustment in respect of prior years: | |||||
UK corporation tax | ( | ||||
Foreign corporation tax | ( | ||||
Total adjustments in respect of prior years | |||||
Deferred tax | |||||
Origination and reversal of temporary differences | ( | ( | |||
Adjustment in respect of prior years – other | ( | ( | |||
( | ( | ( | |||
Tax expense for the year | |||||
Deferred tax charge relating to items recognized in OCI | |||||
Items that may be reclassified subsequently to profit and loss | ( | ||||
Items that will not be recycled to profit and loss | ( | ( | ( | ||
( | ( | ||||
Current tax expense relating to items recognized in Equity | ( | ( | |||
Deferred tax expense relating to items recognized in Equity | ( | ( |
2025 | 2024 | 2023 | |||
$m | $m | $m | |||
Profit before tax from continuing operations | |||||
Expected tax expense based on the standard rate of corporation tax in the UK of 25% (2024: 25%; 2023: 23.5%) | |||||
Explained by: | |||||
Effect of overseas tax rates | ( | ||||
Income not subject to tax | ( | ( | ( | ||
Expenses not deductible for tax purposes | |||||
Non-deductible goodwill adjustments | ( | ||||
Movements in deferred tax not recognized | ( | ||||
Deductible payments on AT1 securities | ( | ( | ( | ||
Tax rate change | ( | ( | |||
Prior year adjustments | ( | ||||
Tax expense for the year |
2025 | 2024 | |
$m | $m | |
Ireland | ||
United Arab Emirates | ||
Total current tax expense related to Pillar II |
2025 | At 1 January | Credited/ (expensed) to the income statement | Recognized on acquisition | Credited to other comprehensive income & equity | At 31 December |
$m | $m | $m | $m | $m | |
Acquired Intangibles | ( | ( | ( | ||
Compensation | |||||
Depreciation in excess of capital allowances | ( | ( | ( | ( | |
Lease accounting | ( | ( | |||
Other short-term timing differences | ( | ( | |||
Revaluation of investments, cash flow hedges and liabilities designated at FVTPL | ( | ( | |||
Share-based payments | ( | ||||
( | ( |
2024 | At 1 January | Credited/ (expensed) to the income statement | Recognized on acquisition | Credited to other comprehensive income & equity | At 31 December |
$m | $m | $m | $m | $m | |
Acquired Intangibles | ( | ( | ( | ||
Compensation | |||||
Depreciation in excess of capital allowances | ( | ( | ( | ||
Lease accounting | |||||
Other short-term timing differences | ( | ||||
Revaluation of investments, cash flow hedges and liabilities designated at FVTPL | ( | ||||
Share-based payments | |||||
( |
2025 | 2024 | |
$m | $m | |
Deferred tax asset | ||
Deferred tax liability | ( | ( |
31 December |
Acquisitions in 2025: | Aarna Capital Limited1,2 | Darton Group Limited | Hamilton Court Group1 | Agrinvest Commodities | Winterflood Securities |
$m | $m | $m | $m | $m | |
Initial cash consideration | — | ||||
Withheld consideration | — | — | — | — | |
Settlement of pre-existing liability | — | — | — | ||
Total consideration | |||||
Fair value of identifiable net assets: | |||||
Intangible assets | — | ||||
Property, plant and equipment | — | ||||
Right of use asset | — | — | |||
Investments | — | — | — | ||
Corporate income tax receivable | — | — | — | — | |
Trade and other receivables | |||||
Inventory | — | — | — | — | |
Equity instruments (unpledged) | — | — | — | — | |
Derivative instruments - asset | — | — | — | ||
Stock borrowing | — | — | — | — | |
Fixed income securities (unpledged) | — | — | — | ||
Cash and cash equivalents | |||||
Trade and other payables | ( | ( | ( | ( | ( |
Stock lending | — | — | — | — | ( |
Short securities | — | — | — | — | ( |
Borrowings | — | ( | — | — | — |
Lease liability | ( | — | ( | — | ( |
Derivative instruments - liability | ( | — | ( | — | — |
Corporate tax | ( | ( | ( | — | — |
Provisions | — | — | — | — | ( |
Deferred tax liability | ( | — | ( | ( | ( |
Deferred Compensation | — | — | — | — | ( |
Non-controlling interest | — | — | ( | — | — |
Total fair value of identifiable assets and liabilities | |||||
Goodwill / (bargain purchase) | ( |
$m | |
Cash consideration paid to non-controlling shareholders | |
Carrying value of the additional interest | ( |
Difference recognized in retained earnings |
Acquisitions in 2024: | Pinnacle Fuel LLC | Dropet | ILS Brokers Limited |
$m | $m | $m | |
Cash consideration | |||
Total consideration | |||
Fair value of identifiable net assets: | |||
Intangible assets | |||
Property, plant and equipment | |||
Right of use asset | |||
Trade and other receivables | |||
Cash and cash equivalents | |||
Trade and other payables | ( | ( | |
Lease liability | ( | ||
Deferred tax liability | ( | ||
Total fair value of identifiable assets and liabilities | |||
Goodwill / (bargain purchase) |
2025 | 2024 | |
$m | $m | |
Cost | ||
At 1 January | ||
Additions during the year | ||
Cost at 31 December | ||
Impairment losses at 1 January | ( | ( |
Foreign currency translation adjustment (CTA) | ||
Net book value at 31 December |
Group Goodwill by CGU | |||
31 December 2025 | 31 December 2024 | ||
CGU (New Allocations) | $m | CGU (Allocations as at 31 December 2024) | $m |
Capital Markets | OTCex | ||
Volcap Trading Partners Limited | |||
Cowen's Prime Services and Outsourced Trading Business | |||
Agriculture | Agriculture | ||
Rosenthal Collins Group1 | |||
USA Clearing | |||
UK Clearing | ProTrader | ||
I.L.S. Brokers Limited | I.L.S. Brokers Limited | ||
X-Change Financial Access LLC | X-Change Financial Access LLC | ||
Energy | Energy | ||
Dropet | |||
Marex Spectron Europe Limited | |||
CSC Commodities UK Limited | CSC Commodities UK Limited | ||
Physical Metals | Recycled Metals | ||
Arfinco S.A. | Arfinco S.A. | ||
Goodwill arising from 2025 acquisitions2 | |||
CGU Allocation | |||
Aarna Capital Limited | |||
Physical Metals | |||
Hamilton Court | |||
Agrinvest | |||
Winterflood4 | |||
Foreign currency translation adjustment (CTA)3 | |||
Total goodwill as at 31 December | Total goodwill as at 31 December | ||
CGU | Pre-tax valuation discount rate | Breakeven discount rate | Valuation revenue growth rate | Breakeven revenue growth rate | Terminal value growth rate | Breakeven terminal value growth rate | Valuation cost growth rate | Breakeven cost growth rate |
Energy | ( | n.m1 | ||||||
CSC Commodities UK Limited | ( | ( | ||||||
Agriculture | ( | |||||||
Physical Metals | ( | ( | ||||||
UK Clearing | ( | n.m1 | ||||||
USA Clearing | ( | n.m1 | ||||||
Arfinco S.A | ||||||||
Capital Markets | ( | n.m1 | ||||||
I.L.S. Brokers Limited | ( | ( | ||||||
X-Change Financial Access LLC | ( | |||||||
Aarna Capital Limited | ( | ( | ||||||
Hamilton Court | ( | ( | ||||||
Agrinvest |
CGU | Pre-tax valuation discount rate | Breakeven discount rate | Valuation revenue growth rate | Breakeven revenue growth rate | Breakeven terminal value growth rate | Valuation cost growth rate | Breakeven cost growth rate | ||||||
Energy | ( | ( | |||||||||||
CSC Commodities UK Limited | ( | ( | |||||||||||
Agriculture | ( | n.m1 | |||||||||||
Volatility Performance Fund S.A. | |||||||||||||
Rosenthal Collins Group | ( | ( | |||||||||||
Volcap Trading Partners Limited | |||||||||||||
X-Change Financial Access LLC | ( | ||||||||||||
Recycled Metals | ( | n.m1 | |||||||||||
ProTrader | ( | n.m1 | |||||||||||
Marex Spectron Europe Limited | ( | n.m1 | |||||||||||
Arfinco S.A. | |||||||||||||
OTCex SA Group | ( | ( | |||||||||||
Cowen's Prime Services and Outsourced Trading Business |
2025 | |
$m | |
Assets classified as held for sale | |
Current assets | |
Trade and other receivables | |
Cash and cash equivalents2 | |
Total current assets | |
Non current assets | |
Goodwill | |
Intangibles | |
Property, plant and equipment | |
Right of use asset | |
Investments | |
Total non current assets | |
Total assets classified as held for sale1 | |
Liabilities classified as held for sale | |
Trade and other payables | |
Lease Liability | |
Total liabilities classified as held for sale1 | |
Net assets classified as held for sale1 |
Customer Relationships1 | Brands | Software | Total | |
$m | $m | $m | $m | |
Cost | ||||
At 1 January 2024 | ||||
Additions on acquisitions | ||||
Additions | ||||
Disposals | ( | ( | ||
At 31 December 2024 | ||||
Additions on acquisitions2 | ||||
Additions | ||||
Disposals | ( | ( | ||
At 31 December 2025 | ||||
Impairment provisions and amortization | ||||
At 1 January 2024 | ||||
Charge for the year | ||||
Disposals | ||||
At 31 December 2024 | ||||
Charge for the year | ||||
Disposals | ( | ( | ||
At 31 December 2025 | ||||
Net book value | ||||
At 31 December 2025 | ||||
At 31 December 2024 |
Pre-tax valuation discount rate | Breakeven discount rate | Compensation payout ratio | Breakeven compensation payout ratio | |
Customer Relationships |
Leasehold improvements | Computer equipment | Furniture, fixtures and fittings | Total | |
$m | $m | $m | $m | |
Cost | ||||
At 1 January 2024 | ||||
Additions on acquisitions | ||||
Additions | ||||
Disposals | ( | ( | ( | ( |
At 1 January 2025 | ||||
Additions on acquisitions | ||||
Additions | ||||
Disposals | ( | ( | ( | ( |
Foreign currency translation adjustment | ||||
At 31 December 2025 | ||||
Depreciation | ||||
At 1 January 2024 | ||||
Charge for the year | ||||
At 1 January 2025 | ||||
Charge for the year | ||||
Disposals | ( | ( | ( | ( |
At 31 December 2025 | ||||
Net book value | ||||
At 31 December 2025 | ||||
At 31 December 2024 |
Leasehold improvements | over the remaining length of the lease or where appropriate |
Computer equipment and other hardware | |
Furniture, fixtures and fittings |
2025 | 2024 | ||
$m | $m | ||
Cost | |||
At 1 January | |||
Additions | |||
Revaluation of investments held at FVTOCI | ( | ||
Change in value of investments held at FVTPL | |||
Disposals | ( | ||
At 31 December | |||
Listed investments | |||
Unlisted investments | |||
At 31 December |
2025 | 2024 | ||
$m | $m | ||
Treasury instruments (non-current) | |||
Treasury instruments (current) | |||
2025 | 2024 | ||
$m | $m | ||
Treasury instruments (non-current) | |||
2025 | 2024 | ||
$m | $m | ||
Reverse repurchase agreements | |||
Treasury instruments | |||
2025 | 2024 | |
$m | $m | |
Treasury instruments (non-current) | ||
Treasury instruments (current) | ||
Treasury instruments (pledged) and assets held under agreements to sell (repledged) - (current) | ||
2025 | 2024 | |
$m | $m | |
Equity instruments (unpledged) | ||
Equity instruments (pledged as collateral) | ||
2025 | 2024 | ||
$m | $m | ||
Cryptocurrency - Trading | |||
Carbon emission certificates and credits - Trading | |||
Warranted metals - Trading | |||
Recyclable scrap metals | |||
Minor metals | |||
Precious metals | |||
Total inventories at fair value less cost to sell |
Cost | Fair value movement | Inventory | |
2025 | 2025 | 2025 | |
$m | $m | $m | |
Cryptocurrency - Trading | ( | ||
Carbon emission certificates and credits - Trading | |||
Warranted metals - Trading | |||
Recyclable scrap metals | |||
Minor metals | |||
Precious metals | |||
Cost | Fair value movement | Inventory | |||
2024 | 2024 | 2024 | |||
$m | $m | $m | |||
Cryptocurrencies | ( | ||||
Carbon emission certificates and credits | |||||
Recyclable scrap metals | ( | ||||
( |
2025 | 2024 | |
$m | $m | |
Fixed income securities (unpledged) | ||
Fixed income securities (pledged) | ||
2025 | 2024 | |
$m | $m | |
Financial Products Program | ||
Tier 2 Program | ||
EMTN Program | ||
Senior Note Program | ||
Financial assets | Financial liabilities | ||||
2025 | 2024 | 2025 | 2024 | ||
$m | $m | $m | $m | ||
Held for trading derivatives carried at fair value through profit and loss that are not designated in hedge accounting relationships: | |||||
Synthetic equity swap | |||||
Agriculture contracts | |||||
Energy contracts | |||||
Foreign currency contracts | |||||
Precious metal contracts | |||||
Credit contracts | |||||
Metals contracts | |||||
Equity contracts | |||||
Crypto contracts | |||||
Rates contracts | |||||
Held for trading derivatives that are designated in hedge accounting relationships: | |||||
Foreign currency contracts | |||||
Rates contracts | |||||
2025 | |||||
Maturity analysis per notional | |||||
Less than 3 months | 3 to 12 months | 1 to 5 years | Over 5 years | Total | |
$m | $m | $m | $m | $m | |
Hedged Risk | |||||
Foreign currency | |||||
Interest rate | |||||
2024 | |||||
Maturity analysis per notional | |||||
Less than 3 months | 3 to 12 months | 1 to 5 years | Over 5 years | Total | |
$m | $m | $m | $m | $m | |
Hedged Risk | |||||
Foreign currency | |||||
Interest rate | |||||
2025 | ||||||||
Hedging instrument | Hedged item | Ineffectiveness | ||||||
Carrying amount | Change in fair value used to calculate hedge ineffectivene ss | Gain/(loss) recognized in OCI | Ineffectiveness (loss) recognized in the income statement | Income statement presentation | ||||
Notional amount1 | Asset | Liability | Balance Sheet presentation | |||||
$m | $m | $m | $m | $m | $m | |||
Hedged Risk | ||||||||
Foreign currency | ( | Derivative instruments | ( | Other expenses | ||||
Interest rate | ( | ( | Net Interest Income | |||||
( | ( | |||||||
2024 | ||||||||
Hedging instrument | Hedged item | Ineffectiveness | ||||||
Carrying amount | Change in fair value used to calculate hedge ineffectivene ss | Gain/(loss) recognised in OCI | Ineffectiveness (loss) recognised in the income statement | Income statement presentation | ||||
Notional amount1 | Asset | Liability | Balance Sheet presentation | |||||
$m | $m | $m | $m | $m | $m | |||
Hedged Risk | ||||||||
Foreign currency | ( | Derivative instruments | ( | Other expenses | ||||
Interest rate | ( | ( | Net Interest Income | |||||
( | ( | |||||||
2025 | |||||
Maturity analysis per notional | |||||
Less than 3 months | 3 to 12 months | 1 to 5 years | Over 5 years | Total | |
$m | $m | $m | $m | $m | |
Hedged Risk | |||||
Interest rate | |||||
2024 | |||||
Maturity analysis per notional | |||||
Less than 3 months | 3 to 12 months | 1 to 5 years | Over 5 years | Total | |
$m | $m | $m | $m | $m | |
Hedged Risk | |||||
Interest rate | |||||
2025 | |||||
Hedging instrument | |||||
Carrying amount | Change in fair value used to calculate hedge ineffectiveness | ||||
Notional amount1 | Asset | Liability | Balance Sheet presentation | ||
$m | $m | $m | $m | ||
Hedged Risk | |||||
Interest rate | ( | Derivative instruments | ( | ||
( | ( | ||||
Hedged item | Ineffectiveness | |||||||
Carrying amount | Accumulated fair value hedge adjustments included in carrying amount | Change in fair value used to calculate hedge ineffectiveness | Ineffectiveness recognized in the income statement | Income statement presentation | ||||
Asset | Liability | Asset | Liability | Balance Sheet presentation | ||||
$m | $m | $m | $m | $m | $m | |||
Hedged Risk | ||||||||
Interest rate | ( | ( | Debt Securities | ( | Net Interest Income | |||
( | Treasury Instruments | ( | ||||||
( | ( | ( | ||||||
2024 | |||||
Hedging instrument | |||||
Carrying amount | Change in fair value used to calculate hedge ineffectiveness | ||||
Notional amount1 | Asset | Liability | Balance Sheet presentation | ||
$m | $m | $m | $m | ||
Hedged Risk | |||||
Interest rate | ( | Derivative instruments | ( | ||
( | ( | ||||
Hedged item | Ineffectiveness | |||||||
Carrying amount | Accumulated fair value hedge adjustments included in carrying amount | Change in fair value used to calculate hedge ineffectiveness | Ineffectiveness recognized in the income statement | Income statement presentation | ||||
Asset | Liability | Asset | Liability | Balance Sheet presentation | ||||
$m | $m | $m | $m | $m | $m | |||
Hedged Risk | ||||||||
Interest rate | ( | Debt Securities | Net Interest Income | |||||
( | — | |||||||
2025 | 2024 | |
$m | $m | |
Reverse repurchase agreements | ||
Repurchase agreements | ( | ( |
( |
2025 | 2024 | ||
$m | $m | ||
Amounts due from exchanges, clearing houses and other counterparties1 | |||
Amounts due from clients1 | |||
Trade debtors1 | |||
Amounts due from Prime Brokers1 | |||
Settlement balances1 | |||
Default funds and deposits | |||
Loans receivable | |||
Other tax and social security taxes | |||
Other debtors | |||
Prepayments | |||
2025 | Current | Less than 30 days | 31 to 60 days | 61 to 90 days | 91 to 120 days | More than 120 days | Total |
Expected credit loss rate | |||||||
Trade debtors $m | |||||||
Trade debtors lifetime ECL $m |
2024 | Current | Less than 30 days | 31 to 60 days | 61 to 90 days | 91 to 120 days | More than 120 days | Total |
Expected credit loss rate | |||||||
Trade debtors $m | |||||||
Trade debtors lifetime ECL $m |
2025 ($m) | Current | Less than 30 days | 31 to 60 days | 61 to 90 days | 91 to 120 days | More than 120 days | Total |
Amounts due from exchanges, clearing houses and other counterparties | |||||||
Amounts due from Prime Brokers | |||||||
Settlement balances | |||||||
Amounts receivable from clients | |||||||
Default funds and deposits | |||||||
Loans receivable | |||||||
Other debtors | |||||||
Corresponding allowance for loan losses ECL |
2024 ($m) | Current | Less than 30 days | 31 to 60 days | 61 to 90 days | 91 to 120 days | More than 120 days | Total |
Amounts due from exchanges, clearing houses and other counterparties | |||||||
Amounts due from Prime Brokers | |||||||
Settlement balances | |||||||
Amounts receivable from clients | |||||||
Default funds and deposits | |||||||
Loans receivable | |||||||
Other debtors | |||||||
Corresponding allowance for loan losses ECL |
2025 | 2024 | ||
$m | $m | ||
At 1 January | |||
Bad debts written off | ( | ( | |
Released to the income statement | ( | ( | |
Charged to the income statement | |||
Other balance sheet movements | |||
At 31 December |
2025 | 2024 | |
$m | $m | |
Amounts due to exchanges, clearing houses and other counterparties1 | ||
Amounts due to Prime Brokers1 | ||
Amounts payable to clients1 | ||
Accruals | ||
Settlement balances1 | ||
Other tax and social security taxes | ||
Other creditors1 | ||
Bank overdrafts | ||
2025 | 2024 | |
$m | $m | |
Short-term borrowings | ||
Long-term borrowings | ||
Total borrowings |
2025 | 2024 | |
$m | $m | |
At 1 January | ||
Additions from Group Acquisitions1 | ||
Repayments | ( | |
Additional draws | ||
Total borrowings |
2025 | 2024 | ||
$m | $m | ||
Segregated assets at banks (not recognized) | |||
Segregated assets at exchanges, clearing houses and other counterparties (not recognized) | |||
Segregated assets at exchanges, clearing houses and other counterparties (recognized) | |||
Group and Company | |||||||
Issued and fully paid | Issued and fully paid | ||||||
2025 | 2025 | 2024 | 2024 | ||||
Number | $'000 | Number | $'000 | ||||
Ordinary Shares of $ | |||||||
Deferred Shares of £ | |||||||
Group and Company | |||||
Ordinary shares Number | Deferred shares Number | Total Number | |||
At 1 January 20251 | |||||
Issuance of shares | |||||
At 31 December 20251 | |||||
Group and Company | |||||||||||
Ordinary shares of $ Number | Ordinary shares of $ Number | Non-voting Ordinary Shares of $ Number | Deferred Shares of £ Number | Growth Shares of $ Number | Total Number | ||||||
At 1 January 2024 | |||||||||||
Ordinary shares reorganization pre-IPO (1) | ( | ( | ( | ||||||||
Total: Post ordinary shares organization | |||||||||||
Reverse share split (2) | ( | ( | |||||||||
Deferred share cancellation (3) | ( | ( | |||||||||
Total: Post share capital organization | |||||||||||
Primary share issuance at IPO1 | |||||||||||
At 31 December 2024 | |||||||||||
Class of share | Rights |
Ordinary Shares | Full voting rights and right to participate in ordinary dividends ranking pari passu with non- voting ordinary shares. In the event of a winding up, entitled to a return of capital ranking pari passu with non-voting ordinary shares and no right of redemption. |
Non-voting Ordinary Shares | As per ordinary shares, other than having no voting rights. |
Deferred Shares | No voting rights, no right to participate in dividends or distributions and no right to redemption. On a return of capital on a winding up or otherwise, the assets of the Company available for distribution to its members shall be applied in paying a sum equal to £ deferred shares pro rata according to the number of deferred shares held by them (rounded to the nearest £ event exceed £ |
Growth Shares | Following its initial public offering, the Company no longer has any growth shares. Growth shares were issued in several series as part of a share-based remuneration scheme. On a liquidity event such as an initial public offering or a sale, the growth shares entitled the holder thereof to a return should the proceeds exceed a specific level, as set for each series on issuance. The holders of growth shares had no voting rights, no rights to participate in dividends, no entitlements to participate in a winding up and could not impact the timing of a liquidity event. The growth shares were redeemable on a liquidity event in cash or by conversion into non-voting ordinary shares, as elected by the holders thereof. In the absence of such an election, the default settlement was conversion into non-voting ordinary shares. Prior to the initial public offering the holders of the growth shares elected to equity settle their awards. |
Reserves | Description |
Revaluation reserve | Cumulative unrealized gains on investments in exchanges that are held at FVTOCI and recognized in equity as well as changes in own credit risk. |
Cash flow hedge reserve | Cumulative unrealized gains and losses on hedging instruments deemed effective cash flow hedges. |
Currency translation reserve | On consolidation, the results of overseas operations are translated into USD at rates approximating to those prevailing when the transactions took place. All assets and liabilities of overseas operations, including goodwill arising on the acquisition of those operations, are translated at the rates ruling at the prevailing date. |
2025 | 2024 | |
$m | $m | |
Deferred Bonus Plan | ||
Retention Long Term Incentive Plan | ||
Annual Long Term Incentive Plan | ||
All Employee Plan | ||
Non-Executive Directors' Plan | ||
Warrants | ||
Total equity-settled share-based payments |
2025 | 2024 | |
Number | Number | |
Outstanding at the beginning of the year | ||
Reverse Share Split | ( | |
Granted during the year | ||
Vested during the year | ( | ( |
Forfeited during the year | ( | ( |
Outstanding at the end of the year | ||
Weighted average fair value of awards granted ($) |
2025 | 2024 | ||||||||
FVTPL | FVTOCI | Amortized cost | Total | FVTPL | FVTOCI | Amortized cost | Total | ||
Financial assets | $m | $m | $m | $m | $m | $m | $m | $m | |
Investments | |||||||||
Treasury instruments | |||||||||
Treasury instruments (pledged) and assets held under agreements to sell (repledged)1 | |||||||||
Fixed income securities | |||||||||
Equity instruments | |||||||||
Derivative instruments2 | |||||||||
Stock borrowing | |||||||||
Reverse repurchase agreements | |||||||||
Amounts due from exchanges, clearing houses and other counterparties | |||||||||
Amounts due from Prime Brokers | |||||||||
Amounts receivable from clients | |||||||||
Settlement balances | |||||||||
Trade debtors | |||||||||
Default funds and deposits | |||||||||
Loans receivable | |||||||||
Other debtors3 | |||||||||
Cash and cash equivalents | |||||||||
2025 | 2024 | ||||||||
FVTPL | FVTOCI | Amortized cost | Total | FVTPL | FVTOCI | Amortized cost | Total | ||
Financial liabilities | $m | $m | $m | $m | $m | $m | $m | $m | |
Repurchase agreements | |||||||||
Derivative instruments | |||||||||
Short securities | |||||||||
Amounts due to exchanges, clearing houses and other counterparties | |||||||||
Amounts due to Prime Brokers | |||||||||
Amounts payable to clients | |||||||||
Settlement balances | |||||||||
Other creditors | |||||||||
Stock lending | |||||||||
Short-term borrowings | |||||||||
Debt securities1 | |||||||||
Lease liability | |||||||||
Bank overdrafts | |||||||||
2025 | 2024 | ||||||||
Level 1 | Level 2 | Level 3 | Total | Level 1 | Level 2 | Level 3 | Total | ||
$m | $m | $m | $m | $m | $m | $m | $m | ||
Financial assets – FVTPL: | |||||||||
Investments | |||||||||
Equity instruments | |||||||||
Treasury instruments | |||||||||
Fixed income securities | |||||||||
Derivative instruments | |||||||||
Amounts receivable from clients | |||||||||
Trade debtors | |||||||||
Reverse repurchase agreements | |||||||||
Stock borrowing | |||||||||
Financial assets – FVTOCI: | — | ||||||||
Investments | |||||||||
Derivative instruments | |||||||||
Financial liabilities – FVTOCI: | — | ||||||||
Derivative instruments | ( | ( | ( | ( | |||||
Financial liabilities – FVTPL: | — | ||||||||
Derivative instruments | ( | ( | ( | ( | ( | ( | |||
Other payables | ( | ( | ( | ( | |||||
Amounts payable to clients | ( | ( | ( | ( | |||||
Short securities | ( | ( | ( | ( | ( | ( | ( | ||
Debt securities | ( | ( | ( | ( | ( | ( | |||
Stock lending | ( | ( | ( | ( | |||||
Repurchase agreements | ( | ( | ( | ( | |||||
( | ( | ( | ( | ( | |||||
2025 | 2024 | ||
$m | $m | ||
Balance at 1 January | |||
Purchases | |||
Settlements | ( | ( | |
Total gains or losses in the period recognized in the income statement: | |||
Market Making revenue | |||
Transfers out of Level 3 | ( | ( | |
Transfers into Level 3 | |||
Balance at 31 December |
2025 | 2024 | ||
$m | $m | ||
Balance at 1 January | |||
Purchases | |||
Settlements | ( | ( | |
Total gains or losses in the period recognized in the income statement: | |||
Market Making revenue | ( | ||
Transfers out of Level 3 | ( | ( | |
Transfers into Level 3 | |||
Balance at 31 December |
Gross amount | Amounts set-off | Net amount presented | Non-cash collateral rec’d/ (pledged) | Cash collateral rec’d/ (pledged) | Net amount | |
2025 | $m | $m | $m | $m | $m | $m |
Financial assets | ||||||
Amounts due from exchanges, clearing houses and other counterparties | ( | |||||
Reverse repurchase agreements | ( | |||||
Derivative instruments | ( | |||||
Treasury instruments (pledged) and assets held under agreements to sell (repledged) | ||||||
Loans receivable | ||||||
Stock borrowing | ||||||
Amounts due from Prime Brokers | ||||||
Amounts receivable from clients | ||||||
Financial liabilities | ||||||
Amounts due to exchanges, clearing houses and other counterparties | ( | |||||
Repurchase agreements | ( | ( | ||||
Derivative instruments | ( | ( | ||||
Stock lending | ( | |||||
Amounts due to Prime Brokers | ( | |||||
Amounts payable to clients | ( | ( | ||||
Gross amount | Amounts set-off | Net amount presented | Non-cash collateral rec’d/ (pledged) | Cash collateral rec’d/ (pledged) | Net amount | |
2024 | $m | $m | $m | $m | $m | $m |
Financial assets | ||||||
Amounts due from exchanges, clearing houses and other counterparties | ( | |||||
Reverse repurchase agreements | ( | |||||
Derivative Instruments | ( | |||||
Treasury instruments (pledged) and assets held under agreements to sell (repledged) | ||||||
Stock borrowing | ||||||
Amounts due from Prime Brokers | ||||||
Amounts receivable from clients | ||||||
Financial liabilities | ||||||
Amounts due to exchanges, clearing houses and other counterparties | ( | |||||
Repurchase agreements | ( | ( | ||||
Derivative Instruments | ( | ( | ||||
Stock lending | ( | |||||
Amounts due to Prime Brokers | ( | |||||
Amounts payable to clients | ( |
December 31, 2025 | December 31, 2024 | |||
Business | VaR | VaR | Additional risk metrics monitored | |
European Emerging Bonds | less than $ | Stress, GMV, DV01, CS01, Aged Inventory | ||
Equities Market Making | less than $ | less than $ | Gross long/short and single name equity delta, FX delta | |
FX Frontier | less than $ | less than $ | FX delta by currency, tenor and book | |
FX OTC | less than $ | less than $ | FX delta by currency, tenor and book | |
Interest Rate Swaps | less than $ | less than $ | PV01 by currency and tenor | |
U.S. Emerging Corporate Bond | less than $ | less than $ | Stress, GMV, DV01, CS01, Aged Inventory | |
U.S. Equity Securities Lending | less than $ | less than $ | Stress, GMV, DV01 | |
U.S. Fixed Income Corporate Bond | less than $ | less than $ | Stress, GMV, DV01, CS01, Aged Inventory | |
U.S. Fixed Income Financing Services | less than $ | less than $ | Stress, GMV, DV01 | |
Marex Fund (Formerly Volatility Performance Fund) | less than $ | less than $ | Equity delta and vega, tenor, FX delta | |
Winterflood- Equities Market Making | less than $ | Gross long/short and single name equity delta, FX delta, DV01 |
December 31, 2025 | December 31, 2024 | |||
Business | VaR | VaR | Additional risk metrics monitored | |
Agricultural | less than $ | less than $ | Outright Delta, Delta spreads, Vega | |
Metals | less than $ | less than $ | Outright Delta, Delta spreads, Vega | |
CSC Commodities | less than $ | less than $ | Outright Delta, Delta spreads, Vega | |
Energy Market Making | less than $ | less than $ | Outright Delta, Delta spreads, Vega, Stress |
FVTPL | FVTOCI | Amortized Cost | Total Financial Assets | ||||||||
AA and above | AA- | A+ | A | A- | BBB+ | Lower and unrated | Total Amortized Cost | ||||
2025 | $m | $m | $m | $m | $m | $m | $m | $m | $m | $m | $m |
Investments | |||||||||||
Treasury instruments | |||||||||||
Treasury instruments (pledged) and assets held under agreements to sell (repledged) | |||||||||||
Fixed income securities | |||||||||||
Equity instruments | |||||||||||
Derivative instruments | |||||||||||
Stock borrowing | |||||||||||
Reverse repurchase agreements | |||||||||||
Amounts due from exchanges, clearing houses and other counterparties | |||||||||||
Amounts due from Prime Brokers | |||||||||||
Amounts receivable from clients | |||||||||||
Settlement balances | |||||||||||
Trade debtors | |||||||||||
Default funds and deposits | |||||||||||
Loans receivable | |||||||||||
Other debtors | |||||||||||
Cash and cash equivalents | |||||||||||
FVTPL | FVTOCI | Amortized Cost | Total Financial Assets | ||||||||
AA and above | AA- | A+ | A | A- | BBB+ | Lower and unrated | Total Amortized Cost | ||||
2024 | 0 | $m | $m | $m | $m | $m | $m | $m | $m | $m | $m |
Investments | |||||||||||
Treasury instruments | |||||||||||
Treasury instruments (pledged) and assets held under agreements to sell (repledged) | |||||||||||
Fixed income securities | |||||||||||
Equity instruments | |||||||||||
Derivative instruments | |||||||||||
Stock borrowing | |||||||||||
Reverse repurchase agreements | |||||||||||
Amounts due from exchanges, clearing houses and other counterparties | |||||||||||
Amounts due from Prime Brokers | |||||||||||
Amounts receivable from clients | |||||||||||
Settlement balances | |||||||||||
Trade debtors | |||||||||||
Default funds and deposits | |||||||||||
Loans receivable | |||||||||||
Other debtors | |||||||||||
Cash and cash equivalents | |||||||||||
Secured borrowings and committed revolving credit facilities: | 2025 | 2024 | ||
$m | $m | |||
Amount used | 27 | |||
Amount unused | 27 | |||
On demand | Less than 3 months | 3 to 12 months | 1 to 5 years | More than 5 years | Total | |
2025 | $m | $m | $m | $m | $m | $m |
Repurchase agreements | ||||||
Short securities | ||||||
Amounts due to exchanges, clearing houses and other counterparties1 | ||||||
Amounts due to Prime Brokers1 | ||||||
Amounts payable to clients1 | ||||||
Other creditors1 | ||||||
Stock lending | ||||||
Settlement balances1 | ||||||
Short-term borrowings | ||||||
Debt securities | ||||||
Lease liabilities | ||||||
Bank overdrafts | ||||||
On demand | Less than 3 months | 3 to 12 months | 1 to 5 years | More than 5 years | Total | |
2024 | $m | $m | $m | $m | $m | $m |
Repurchase agreements | ||||||
Short securities | ||||||
Amounts due to exchanges, clearing houses and other counterparties1 | ||||||
Amounts due to Prime Brokers1 | ||||||
Amounts payable to clients1 | ||||||
Other creditors1 | ||||||
Stock lending | ||||||
Settlement balances1 | ||||||
Short-term borrowings | ||||||
Debt securities | ||||||
Lease liabilities | ||||||
2025 | On demand $m | Less than 3 months $m | 3 to 12 months $m | 1 to 5 years $m | More than 5 years $m | Total $m | |||||
Treasury instruments | |||||||||||
Treasury instruments (pledged) and assets held under agreements to sell (repledged) | |||||||||||
Fixed income securities | |||||||||||
Equity instruments | |||||||||||
Stock borrowing | |||||||||||
Reverse repurchase agreements | |||||||||||
Amounts due from exchanges, clearing houses and other counterparties1 | |||||||||||
Amounts due from Prime Brokers1 | |||||||||||
Amounts receivable from clients1 | |||||||||||
Settlement balances1 | |||||||||||
Trade debtors1 | |||||||||||
Default funds and deposits1 | |||||||||||
Loans receivable1 | |||||||||||
Other debtors1 | |||||||||||
Cash and cash equivalents | |||||||||||
2024 | On demand $m | Less than 3 months $m | 3 to 12 months $m | 1 to 5 years $m | More than 5 years $m | Total $m | |||||
Treasury instruments | |||||||||||
Treasury instruments (pledged) and assets held under agreements to sell (repledged) | |||||||||||
Fixed income securities | |||||||||||
Equity instruments | |||||||||||
Stock borrowing | |||||||||||
Reverse repurchase agreements | |||||||||||
Amounts due from exchanges, clearing houses and other counterparties1 | |||||||||||
Amounts due from Prime Brokers1 | |||||||||||
Amounts receivable from clients1 | |||||||||||
Settlement balances1 | |||||||||||
Trade debtors1 | |||||||||||
Default funds and deposits1 | |||||||||||
Loans receivable1 | |||||||||||
Other debtors1 | |||||||||||
Cash and cash equivalents | |||||||||||
2025 | On demand | Less than 3 months | 3 to 12 months | 1 to 5 years | 5 + years | Total | |||||
Derivative instruments | $m | $m | $m | $m | $m | $m | |||||
Assets | |||||||||||
Liabilities | ( | ( | ( | ( | ( | ||||||
( | ( |
2024 | On demand | Less than 3 months | 3 to 12 months | 1 to 5 years | 5 + years | Total | |||||
Derivative instruments | $m | $m | $m | $m | $m | $m | |||||
Assets | |||||||||||
Liabilities | ( | ( | ( | ( | ( | ||||||
( |
2025 | 2024 | 2023 | |||
$m | $m | $m | |||
Aggregate wages and salaries | |||||
Short-term monetary benefits | |||||
Defined contribution pension cost | |||||
Management Incentive plan | |||||
Right-of-use asset | |||
2025 | 2024 | ||
$m | $m | ||
As at 1 January | |||
Additions during the year | |||
Incentive of right-of-use asset | ( | ||
Adjustment to initial recognition of right of use asset | |||
Depreciation charged to income statement | ( | ( | |
Impairment of right of use asset | ( | ( | |
As at 31 December | |||
Lease liability | |||
2025 | 2024 | ||
$m | $m | ||
As at 1 January | |||
Additions during the year | |||
Interest expense charged to income statement | |||
Payment of lease liabilities | ( | ( | |
Foreign exchange revaluation | ( | ||
Lease incentive | |||
As at 31 December | |||
Lease liability | |||
2025 | 2024 | ||
$m | $m | ||
Current liability | |||
Non-current liability | |||
As at 31 December | |||
Lease liability | |||
2025 | 2024 | ||
$m | $m | ||
1 year | |||
1 to 5 years | |||
More than 5 years | |||
Less: future interest expense | ( | ( | |
2025 | 2024 | 2023 | |||
$m | $m | $m | |||
Interest income | |||||
Interest expense | ( | ( | ( | ||
Net interest income | |||||
Dividend income | |||||
Expenses: | |||||
Impairment of investments in subsidiaries | ( | ( | ( | ||
Other income | |||||
Other expenses | ( | ( | ( | ||
Profit/(loss) before tax | ( | ||||
Tax | ( | ( | ( | ||
Profit/(loss) after tax | ( | ||||
Other comprehensive profit/(loss) | ( | ( | |||
Total comprehensive income/(loss) | ( |
2025 | 2024 | ||||
$m | $m | ||||
Assets | |||||
Non-current assets | |||||
Investments | |||||
Investments in subsidiaries | |||||
Deferred tax | |||||
Subordinated loans due from group undertakings | |||||
Total non-current assets | |||||
Current assets | |||||
Trade and other receivables | |||||
Derivative instruments | |||||
Cash and cash equivalents | |||||
Total current assets | |||||
Total assets | |||||
Liabilities | |||||
Current liabilities | |||||
Trade and other payables | |||||
Derivative instruments | |||||
Corporation tax | |||||
Debt securities | |||||
Total current liabilities | |||||
Non-current liabilities | |||||
Debt securities | |||||
Total non-current liabilities | |||||
Total liabilities | |||||
Total net assets | |||||
Equity | |||||
Share capital | |||||
Share premium | |||||
Retained earnings | |||||
Own shares | ( | ( | |||
Other reserves | ( | ( | |||
Total equity attributable to the ordinary shareholders of the Company | |||||
Additional Tier 1 capital (AT1) | |||||
Total equity |
2025 | 2024 | 2023 | ||||
$m | $m | $m | ||||
Profit / (loss) before tax | ( | |||||
Adjustments for non-cash items: | ||||||
Impairment of investments in subsidiaries | ||||||
Bargain purchase gain on acquisitions | ( | |||||
Share-based compensation expense | ||||||
Other non-cash movements including exchange rate movements | ( | ( | ||||
Changes in operating assets and liabilities | ||||||
Increase in trade and other receivables | ( | ( | ( | |||
Increase /(decrease) in trade and other payables | ( | |||||
Net (increase) / decrease in derivative instruments | ( | ( | ||||
Increase in equity instruments | ( | ( | ( | |||
Increase in debt securities | ||||||
Corporation tax paid | ( | ( | ||||
Net cash (used in) / from operating activities | ( | ( | ||||
Investing activities | ||||||
(Increase)/decrease in subordinated loan receivable | ( | |||||
Net cash from / (used in) investing activities | ( | |||||
Financing activities | ||||||
Proceeds from issuance of ordinary shares | ||||||
Issuance costs of ordinary shares | ( | |||||
Purchase of own shares | ( | ( | ( | |||
Dividends paid | ( | ( | ( | |||
Net cash used in financing activities | ( | ( | ( | |||
Net (decrease) / increase in cash and cash equivalents | ( | |||||
Cash and cash equivalents | ||||||
Cash at banks and on hand and short-term deposits at 1 January | ||||||
(Decrease) / increase in cash | ( | |||||
Cash and cash equivalents at 31 December |

FAQ
What does Marex Group plc (MRX) disclose in its latest Form 20-F?
How many Marex Group plc ordinary shares are outstanding according to the filing?
Which accounting standards does Marex Group plc (MRX) use in its Form 20-F?
What are the main market and macroeconomic risks highlighted by Marex Group plc?
How is Marex Group plc exposed to regulatory and compliance risk?
What cybersecurity and technology risks does Marex Group plc report?
How is Marex Group plc involved with cryptocurrencies according to the Form 20-F?